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Abstract 
New drugs are needed to combat the ever-increasing incidence of drug resistant tuberculosis.  
Eukaryotes and Gram negative bacteria make use of a low molecular weight thiol-containing 
peptide, glutathione (GSH), in their defense against toxins and oxidative stress.  In 
mycobacteria a carbohydrate-based thiol, mycothiol (MSH), is used instead.   
MshB catalyses the third step in the mycothiol biosynthetic pathway which involves the 
deacetylation of 1-O-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-D-myo-inositol (GlcNAc-
Ins), via cleavage of an amide bond, to 1-O-(2-amino-2-deoxy-α-D-glucopyranosyl)-D-myo-
inositol (GlcN-Ins) and acetate.  MshB is a homolog of another zinc-dependent amidase, 
mycothiol S-conjugate amidase (Mca), which recycles GlcNAc-Ins by cleaving the similarly 
located amide bond after mycothiol has reacted with an electrophile. The enzymes have 
overlapping enzyme activity and their products feed into the same step of the mycothiol 
synthetic pathway.  Structure-based drug design could potentially be used to develop leads 
that could inhibit both enzymes simultaneously.   
This study was motivated by the need to visualise a putative inhibitor bound to MshB.  An 
attempt was made to co-crystallise VU5 and MshB.  VU5, which comprises plumbagin 
tethered to a thiophenylglycoside by five methylene carbons, was found by Gammon et al. 
(2010) to be an inhibitor of MshB and Mca.   
Diffraction quality crystals were grown and data were collected at the ESRF synchrotron 
facility.  The crystal structure was solved by molecular replacement and most notably, 
glycerol and acetate (a product of the natural reaction) was found bound in the active site.  
This allowed a greater understanding regarding important residues involved in substrate 
binding and the catalytic mechanism. 
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The findings presented here provide some insight into the substrate binding mechanism and 
support a recent publication that infers that Tyr-142 plays an important role in the catalytic 
mechanism, as well as suggesting that VU5 may behave as a substrate and that DTT may act 
as an inhibitor. 
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1 Introduction 
1.1 Tuberculosis 
A third of the world’s population is estimated to be carrying latent Mycobacterium 
tuberculosis (M. tb), the bacteria responsible for causing tuberculosis (TB).  Mycobacterium 
tuberculosis is an aerobic, non-mobile bacteria that is characterised by acid fast detection, as 
gram staining is made difficult by a high mycolic acid content in the cell wall.  TB was 
responsible for 1.7 million deaths worldwide in 2009, not taking into account 22 African 
countries that have no data reported (WHO 2011).  TB has a high incidence of antibacterial 
resistance which is increased by patient non-compliance.  South Africa is regarded by the 
World Health Organization (WHO) as one of twenty seven high burden countries for multi 
drug resistant tuberculosis (MDR-TB).  MDR-TB is defined as infection by bacteria that are 
resistant to the most effective anti-TB drugs (isoniazid and rifampicin).  South Africa is also 
one of the countries affected by the occurrence of extremely drug resistant tuberculosis 
(XDR-TB).  XDR-TB is a form of tuberculosis caused by bacteria that are resistant to 
isoniazid and rifampicin, as well as any fluoroquinolone and any of the second-line anti-TB 
injectable drugs (amikacin, kanamycin or capreomycin) (WHO 2011).  The drugs used to 
combat MDR- and XDR-TB are more expensive, less effective and more toxic than the first 
line drugs.   
M. tb most often infects the lungs (pulmonary tuberculosis), but there have been cases where 
it has affected almost every organ in the body.  It is primarily spread by the transfer of water 
droplets carrying the bacteria in the air from one person to another.  In a healthy person, the 
immune system is most often able to overcome the primary infection.  However the bacteria 
can lie dormant in the human host for years before an opportunity arises where the bacteria 
can cause an active infection again.  On average it is estimated that 5 % of people carrying 
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the latent bacteria will develop the active disease again within two years, and 5 % will 
develop the active disease after two years.  In patients that are immune deficient, as in the 
case of people infected with Human Immune Virus (HIV), this estimate increases to 10 % re-
activation every year (Figure 1-1) (Small, Fujiwara 2001). 
 
Figure 1-1: Transmission and progression of TB.   
Adapted from (Small, Fujiwara 2001) 
TB is transmitted primarily by airborne droplets of water carrying the bacteria.  The skin test for TB will show 
positive for infection in six to eight weeks.  In immuno-competent individuals, the body’s immune system can 
often overcome the primary infection but can also lead to latent TB.  The latent bacteria progress to full TB 
again in 5 % of cases within two years, and in 5 % of cases after two years.  This increases to 10 % for each year 
in patients concurrently infected with HIV.  
 
Transmission Primary 
Tuberculosis 
Latent Tuberculosis “Re-activation” Tuberculosis 
Skin test conversion in 
6 to 8 weeks Spontaneous healing in 
6 months 
5 % Progression 
after 2 years 
5 % Progression 
within 2 years 
10 % Progression each 
year with concurrent 
HIV infection 
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There are many compounding challenges that face the treatment of TB.  In the late 1980’s it 
was noticed that many patients infected with TB were defaulting on taking their medication 
due to the adverse side effects that the drugs caused.   
The canonical treatment of TB requires a combination of drugs to be administered to the 
patient, which lends its own difficulties and complications when trying to encourage patients 
to finish their course of medication.  Table 1-1 contains a list of the most common drugs and 
associated side effects that are used to cure TB infected patients. 
The time needed for patients to complete a course of medication that leads to clearing of the 
current infection usually takes about 6 to 9 months.  The time factor combined with the side 
effects increases the number of people who stop taking their medication prematurely.  As 
mentioned previously, this then increases the likelihood of resistant TB infections emerging. 
TB is often found in patients who are concurrently infected with HIV, due to their 
compromised immune system.  The problem with this is that some TB drugs interact with 
anti-retroviral drugs in a negative way (Aaron et al. 2004).  For example, when rifampicin is 
administered together with anti-retrovirals, this causes sub-therapeutic blood levels of anti-
retroviral drugs and toxic levels of rifampicin (Small, Fujiwara 2001). 
Commercial drug companies perceive a lack of profit opportunity because the highest number 
of new cases of TB are in under-developed countries, with the African region having the 
highest incidence per 100 000 population (WHO 2011), while the number of incidences in 
the developed world is decreasing.  Combined with this is the inherent cost of developing 
new drugs, which is estimated to be anywhere between US$ 161 million and US$ 1.8 billion 
(Morgan et al. 2011).  There is also a perceived problem facing clinical trials; few products 
have been newly registered for the treatment of TB in the past three decades and thus 
previous guidelines are seen as outdated and current guidelines are often poorly defined 
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(O'Brien, Nunn 2001). Lead discovery is currently a bottleneck in the pipeline for much 
needed novel drugs for diseases such as malaria and tuberculosis (Nwaka and Hudson 2006).   
To ensure compliance and enhance positive treatment, new drugs are needed to either 
increase the sensitivity of TB to current drugs, or kill the bacteria independently.  It would be 
best if these new drugs also target pathways or enzymes that are not present in the host and 
therefore will not have as many adverse drug interactions as the current therapies.  This 
would shorten the regimen needed for successful treatment.  New drugs may decrease the 
cost of treating TB and decrease the duration of treatment with drugs which cause the patient 
to feel ill and therefore increase the compliance and treatment rate.   
One of the pathways that are of interest with respect to investigating drug targets is the 
mycothiol biosynthetic pathway of M. tb.   
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
20 
 
Table 1-1: Adverse side effects of current first and second line drugs used to cure TB 
Drug Adverse Side effects§ Comments 
First Line Medication   
Isoniazid Elevated hepatic enzymes, peripheral neuropathy, 
hepatitis, central nervous system (CNS) effects. 
Overdose may be fatal. 
Rifampicin Hepatitis, fever, reduces blood levels of many drugs 
including warfarin, birth control pills, protease 
inhibitors and non-nucleoside reverse-transcriptase 
inhibitors. 
Causes orange discolouration of secretions, 
interactions with many drugs lead to decreased 
levels of rifampicin.  May complicate management 
of diabetes. 
Pyrazinamide Gastrointestinal (GI) disturbance, hepatic effects, rash. May complicate management of diabetes. 
Ethambutol Decreased red-green discrimination, decreased visual 
acuity, rash. 
Toxicity in the eyes may be unilateral therefore 
each eye must be checked separately. 
Streptomycin Auditory, vestibular and renal effects, electrolyte 
effects. 
 
Second Line Medication   
Capreomycin Auditory, vestibular and renal effects, electrolyte 
effects. 
 
Ciprofloxacin¶ GI disturbance, insomnia, headache, photosensitivity, 
interactions with warfarin. 
Variable absorption, increased caffeine effects. 
Clofazimine¶ GI symptoms that can mimic appendicitis, visual 
disturbances in rare cases. 
Efficacy unproved, causes orange-brown 
discolouration of skin. 
Cycloserine Psychosis, seizures, headache, depression, rash, other 
CNS effects. 
 
Ethionamide GI disturbance, bloating, hepatoxic effects, 
hypothyroidism. 
 
Kanamycin/amikacin¶ Auditory and renal toxic effects, vestibular effects, 
electrolyte effects. 
 
Levofloxacin¶ Similar to effects of ciprofloxacin. Variable absorption, increased caffeine effects. 
Ofloxacin¶ Probably similar to effects of ciprofloxacin. Variable absorption, increased caffeine effects. 
Aminosalicylic acid GI disturbance, hypersensitivity, hepatoxic effects, 
hypothyroidism. 
 
Rifabutin¶ Rash, hepatitis, fever, reduces levels of many drugs 
including protease inhibitors, non-nucleoside reverse-
transcriptase inhibitors and birth control pills. 
Causes orange discolouration of body fluids 
Rifapentine Nausea, vomiting, dizziness, rash, elevated values on 
liver function tests. 
Cross-resistance with rifampicin, induces 
cytochrome P-450 system, causes orange 
discolouration of body fluids. 
Notes: 
§ Not all toxic effects are listed. 
¶ The drug has not been approved by the USA Food and Drug Administration for the treatment of tuberculosis. 
Adapted from “Management of tuberculosis in the United States” Small and Fujiwara, 2001 (Small, Fujiwara 2001). 
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1.2 Mycothiol 
Eukaryotes and gram negative bacteria make use of a low molecular weight thiol called 
glutathione (GSH) in their defence against toxins and oxidative stress (Forman, Zhang & 
Rinna 2009).  The major low molecular weight thiol in mycobacteria, however, is 1D-myo-
inosityl-2-(N-acetyl-L-cysteinyl)amido-2-deoxy-α-D-glucopyranoside (MSH, Figure 1-2).   
 
Figure 1-2: Structure of mycothiol 
1D-myo-inosityl-2-(N-acetyl-L-cysteinyl)amido-2-deoxy-α-D-glucopyranoside (mycothiol or MSH) (Figure 
adapted from Newton and Fahey (2002)).  MSH is a conjugate of N-acetylcysteine (AcCys) with 1-D-myo-
inosityl-2-amino-2-deoxy-α-D-glucopyranoside (GlcN-Ins) (Newton et al. 1996).  
 
The common name mycothiol was proposed by Spies and Steenkamp (1994).  MSH is a 
conjugate of N-acetylcysteine (AcCys) with 1-D-myo-inosityl-2-amino-2-deoxy-α-D-
glucopyranoside (GlcN-Ins) (Newton et al. 1996).  MSH is involved in a variety of different 
cellular processes, including detoxification of electrophilic compounds, inactivation of 
reactive oxygen and nitrogen species, reductions and implicated to be involved in the 
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isomerisation of maleylpyruvate to fumarylpyruvate in some actinomycetes including 
Corynebacterium spp. (Newton, Buchmeier & Fahey 2008).   
By analogy to GSH, MSH is proposed be very important in the protection of cells from a 
variety of toxins and reactive oxygen species. It has been shown that MSH deficient strains of 
Mycobacterium spp. are sensitive to stress (Rawat et al. 2002, Newton, Av-Gay & Fahey 
2000, Buchmeier et al. 2003, Hayward, Wiid & van Helden 2004).  Preventing bacteria from 
protecting themselves from toxic levels of reactive oxygen species that are abundant in an 
aerobic environment will also help in crippling dormant M. tb.  In addition, some genes in the 
mycothiol biosynthesis pathway are essential for the growth of M. tb, namely mshA and mshC 
(Buchmeier, Fahey 2006, Sareen et al. 2003).   
MSH is important to mycobacteria and since there is no MSH pathway in humans, it is 
possible that MSH biosynthesis can be inhibited in the bacterium without affecting the human 
host.  This makes the MSH biosynthesis pathway a potential target for novel TB drugs 
(Duncan, 2004).   
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1.3 MSH biosynthetic pathway 
The MSH pathway starts with the conjugation of 1L-myo-inositol-1-phosphate (Ins-P) to 
uridine-diphosphate-N-acetyl-glucosamine (UDP-GlcNAc), catalysed by MshA. Uridine-
diphosphate (UDP) is removed during the reaction and the product formed is 1-O-(2-
acetamido-2-deoxy-α-D-glucopyranosyl)-D-myo-inositol-3-phosphate (GlcNAc-Ins-P) 
(Newton et al. 2003, Newton et al. 2006).  The second step is catalyzed by an enzyme that 
has yet to be identified (but has been referred to as MshA2), and involves the 
dephosphorylation of GlcNAc-Ins-P to form 1-O-(2-acetamido-2-deoxy-α-D-
glucopyranosyl)-D-myo-inositol (GlcNAc-Ins) (Newton, Buchmeier & Fahey 2008).  The 
third step involves the deacetylation of GlcNAc-Ins to 1-O-(2-amino-2-deoxy-α-D-
glucopyranosyl)-D-myo-inositol (GlcN-Ins) by MshB (Newton, Av-Gay & Fahey 2000).  The 
fourth step is catalysed by MshC and entails the ATP-dependent ligation of cysteine with 
GlcN-Ins to form 1-O-[2-[[(2R)-2-amino-3-mercapto-1-oxopropyl]amino]-2-deoxy-α-D-
glucopyranosyl]-D-myo-inositol (Cys-GlcN-Ins) (Sareen et al. 2002).  The fifth and final step 
in MSH biosynthesis results in the acetylation of the amino group of cysteine in Cys-GlcN-
Ins by acetyl-CoA.  This step is catalyzed by MshD and yields the final product 1D-myo-
inosityl-2-(N-acetyl-L-cysteinyl)amido-2-deoxy-α-D-glucopyranoside (MSH) (Koledin, 
Newton & Fahey 2002).  Figure 1-3 provides a graphical overview of the biosynthetic 
pathway and shows the substrates, products and known protein structures.   
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Figure 1-3: MSH biosynthetic pathway.   
The five step biosynthesis of MSH is shown, adapted from Jothivasan and Hamilton (2008).  The pathway 
begins with the conjugation of Ins-P to GlcNAc by MshA, followed by the removal of phosphate by a 
hypothetical protein MshA2.  The acetyl group is then removed by MshB and a cysteine is added by MshC.  
Finally MshD catalyses the addition of another acetyl group. 
(A) MshA: The structure of MshA from Corynebacterium glutamicum is shown (PDB ID: 3C4Q).  (B) MshB: 
The structure of MshB from M. tb is shown (PDB ID: 1Q74).  (C) MshC: The structure of MshC from 
Mycobacterium smegmatis is shown (PDB ID: 3C8Z).  (D) MshD: The structure of MshD from M. tb is shown 
(PDB ID: 1OZP). 
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1.4 MSH-dependent enzymes 
In one well-studied pathway (Figure 1-4), MSH forms conjugates with various toxins and 
antibiotics via the reactive sulphur and forms a compound referred to as MSR (Buchmeier et 
al. 2003, Steffek et al. 2003).  MSH S-conjugate amidase (Mca) cleaves these conjugates 
producing GlcN-Ins and mercapturic acid.  GlcN-Ins is then recycled to make more MSH by 
re-entering the MSH biosynthetic pathway via MshC.  The mercapturic acid is a conjugate of 
the toxin and the acetyl cysteine and is thought to be excreted from the bacteria in a similar 
fashion to the GSH detoxification pathway (Newton, Fahey 2002).  No Mca mutants have 
been reported in M. tb so far, but Mca mutants in Mycobacterium smegmatis (M. smegmatis) 
have been shown to have increased sensitivity to a variety of toxins and antibiotics (Rawat et 
al. 2004).  This pathway is thought to be a route of antibiotic resistance and would therefore 
also be a good drug target. 
 
Figure 1-4: The role of Mca in recycling GlcNAc-Ins.   
MSH forms conjugates (termed MSR) with toxins and antibiotics (R1-X).  MSR is a substrate of Mca.  The 
products of the reaction where MSR is hydrolysed by Mca are a mercapturic acid, which is a conjugate of the 
toxin (R) and the acetyl cysteine (AcCys), and GlcN-Ins, which is then recycled back into the biosynthetic 
pathway.   
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1.5 MSH-related drug targets 
As MshA and MshC are considered essential to M. tb, these proteins would be good drug 
targets.  The first obstacle with these targets is that there are no structures currently reported 
of these M. tb enzymes, which makes structure-based drug design difficult.  There are 
however structures of these targets reported in other related organisms.   
MshA has been solved from Corynebacterium glutamicum (C. glut) to a resolution of 2.8 Å 
(PDB ID 3C4Q).  MshA is related to the GT-B structural family whose members have two 
domains with both domains showing a Rossmann-type fold.  The Rossmann fold is a 
common three layer fold consisting of a β sheet layer sandwiched between two layers of α 
helices.  According to a multiple alignment using the online Basic Local Alignment Search 
Tool (BLAST) (Altschul et al. 1997, Altschul et al. 2005), the C. glut MshA and the M. tb 
MshA share 51 % identity, and 74 % of the amino acids that are within 5 Å of the active site 
bound ligands in chain A of 3C4Q are the same.  The similarities are in favour for potentially 
successful modeling attempts.  If the measure of success of a model is a situation when the 
position of the C-α backbone atoms have an r.m.s.d. less than 2 Å when compared to the 
template, then protein structure templates for homology modeling are generally considered 
successful templates if they share more than 50 % sequence identity with the target protein to 
be modelled (Schwede et al. 2000, Eswar et al. 2006).  Therefore a potentially successful 
model could be built, however a great limitation to evaluating drugs that target MshA, is the 
difficulty in obtaining active purified MshA from M. tb (Newton, Buchmeier & Fahey 2008).   
MshC from M. smegmatis was solved to a resolution of 1.6 Å (PDB ID 3C8Z).  The MshC 
tertiary structure resembles that of cysteinyl-tRNA synthetase, with a Rossman fold catalytic 
domain.  Statistics from a BLAST search indicate that MshC from M. smegmatis shares 79 % 
identity to the MshC from M. tb, and 95 % of the amino acids that are within 5 Å of the 
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active site bound ligands in chain A of 3C8Z are the same.  Due to the high sequence identity 
between the published structure and the protein of interest in M. tb, MshC in M. tb could be 
modelled fairly accurately using MshC from M. smegmatis as a template.   
In one study a high-throughput screen identified lead molecules that could inhibit MshC 
(Newton et al. 2006).  One hit, NTF1386, was found to interact well with MshC (Fahey et al. 
2008).  M. smegmatis treated with the MshC inhibitor NTF1836 produced less MSH but also 
showed reduced growth of the bacteria.  This is important to note as MSH is not essential for 
growth in M. smegmatis (Newton, Buchmeier & Fahey 2008).  Therefore current inhibitors of 
MshC are also likely to affect other essential pathways, which is advantageous in one sense 
as it would be unlikely for the bacteria to develop resistance t  a drug that affects two 
essential pathways.  However inhibitors of MshC are also likely to inhibit cysteinyl-tRNA 
transferase, which could be the cause of the reduced growth in the aforementioned study, but 
which is also present in humans (Newton, Buchmeier & Fahey 2008) and thus would more 
than likely cause considerable harm to the human host (a particularly undesirable trait in a 
drug lead) as well as the pathogen.   
The next likely target is MshD.  Its structure has been solved in M. tb and the tertiary 
structure consists of two tandem-repeated domains, each resembling the Gcn5-related N-
acetyltransferase (GNAT) fold.  MshD mutants are among the most sensitive mutants 
surveyed for survival in mouse macrophages (Rengarajan, Bloom & Rubin 2005), however 
MshD is not essential for M. tb growth (Buchmeier, Newton & Fahey 2006), and knockout 
strains still produce small amounts of MSH.  No drugs have been reported that are active 
against MshD. 
MshB is the last enzyme of the MSH biosynthetic pathway that will be discussed here.  The 
structure of MshB closely resembles the Rossman fold of lactate dehydrogenase, although it 
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is interesting to note that MshB does not have a related fold among the known zinc-
dependent enzymes (Maynes et al. 2003).   
Some authors suggest that MshB is not a suitable drug target, reasons for this include the 
finding that MshB is not essential for the growth of M. tb and MshB mutants still produce 
MSH (most likely due to activity of an homologous enzyme, Mca) and show resistance to 
isoniazid and ethionamide (Xu et al. 2011).  Isoniazid and ethionamide are pro-drugs that 
require activation by a catalytic peroxidise (katG) or by a flavoprotein monoxygenase; the 
mechanism by which the MSH pathway participates in the activation of these two drugs is 
unclear (Newton, Buchmeier & Fahey 2008).   
Results have shown however that MshB mutants are sensitive to a range of other toxins 
including rifampicin and that MshB acts as a rate limiting step controlling the amount of 
MSH produced by way of a negative feedback loop (Buchmeier et al. 2003).  MshB seems to 
be the most likely target in the mycothiol biosynthetic pathway, it has also previously been 
studied at the University of Cape Town and therefore will be the object of this research.  
MshB is also a very close homologue to Mca, and inhibitors that act against both of these 
enzymes simultaneously could be highly detrimental to the viability of M. tb and therefore 
lead to potential drug development.   
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1.6 MshB and Mca 
MshB in M. tb was the first enzyme to be discovered in the MSH biosynthetic pathway and 
was found as a homologue to the M. smegmatis Mca (Newton, Av-Gay & Fahey 2000).  Mca 
and MshB are similar in a number of ways.  According to a multiple alignment using the 
online Basic Local Alignment Search Tool (BLAST), the M. tb Mca (taxonomy ID 1773) and 
MshB share 43% amino acid homology over the first 200 residues.  Secondly, they are both 
Zn
2+
 metalloproteins.  Thirdly there is evidence for a slight overlap in substrate specificity 
(Steffek et al. 2003, Newton et al. 2006).   
There is currently no structure reported for Mca.  Due to the similarities between Mca and 
MshB, drug leads that are produced using the MshB structure could potentially be used to 
stabilise the Mca enzyme enough for it to be crystallised, that is of course if the problem 
surrounding crystallisation of Mca is due to the fact that there are flexible loops around the 
active site that prevent it from crystallising readily.  An Mca structure would add a great deal 
of insight into the binding mechanism of substrates and contribute significantly to the 
knowledge surrounding MSR metabolism.   
Newton, Buchmeier and Fahey (2008) inferred that Mca was not essential to M. tb by 
referencing a study by Sassetti, Boyd & Rubin (2003), however the Sassetti study assumed 
that genes were only to be considered essential, if they were essential to both Mycobacterium 
bovis and M. tb.  However, it is known that homologous MSH biosynthetic enzymes that are 
not essential in M. smegmatis, are essential in M. tb.  For example, MshC mutants can be 
found in M. smegmatis, but not in M. tb (Sareen et al. 2003 and Rawat et al. 2002).  
Therefore citing the results of the Sassetti study as a reason to ignore Mca as a potential drug 
target would not be entirely correct. 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
30 
 
In vitro experiments have shown that Mca is able to cleave the natural substrate of MshB, and 
it is thought to be an alternative route to MSH in M. tb mutants deficient in MshB 
(Buchmeier et al. 2003).  However it must be noted that recombinant Mca that is over-
expressed in a mutant lacking MshB in M. smegmatis was unable to recover wild type levels 
of MSH (Rawat et al. 2003).   
A recent study has shown that M. smegmatis mutants with a double deletion of mshB and mca 
produced no detectable MSH (Xu et al. 2011).  Inhibiting these enzymes could mean that no 
MSH would be produced, and therefore the bacteria would not be able to excrete toxins and 
agents that cause oxidative stress via this route and thus would be more sensitive to pro-
oxidant drugs.   
This has led to a focus on identifying and producing chemicals that inhibit both MshB and 
Mca as possible leads for drugs in the treatment of tuberculosis (Newton, Av-Gay & Fahey 
2000, Steffek et al. 2003, Newton et al. 2006, Fetterolf, Bewley 2004, Gammon et al. 2003, 
Knapp et al. 2002, Nicholas et al. 2003, Nicholas et al. 2002, Nicholas et al. 2001, Pick et al. 
2006, Metaferia et al. 2007b, Metaferia et al. 2007a, Gammon et al. 2010).   
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1.7 Structure-based drug design 
In order to design drugs rationally, ideally an enzyme structure is needed with a transition 
state substrate bound in the active site.  This provides information regarding important 
pharmacophores that are available in the active site and implicates the mechanism by which 
the substrates are processed.  Based on that information one can perform in silico drug 
screens and formulate a few drug leads that should effectively inhibit the enzyme and 
decrease the cost of empirically screening hundreds of random small molecules.   
 
Unfortunately, up until now, no-one has been able to visualise either substrate or inhibitors in 
the active site of MshB, and no-one has reported a crystal structure of Mca.  Attempts to 
model the active site of Mca have revealed very little with regards to the changes that could 
be causing the differences in substrate specificity (Maynes et al. 2003).  Therefore, there has 
been little investigation into structure-based drug design for inhibitors of both MshB and 
Mca.  Structure based drug design depends on knowledge of inhibitor binding and the 
mechanism of action, therefore an analysis will be made of the present state of knowledge of 
MshB and Mca. 
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1.8 Structure and mechanism of MshB 
In August of 2003 two groups published the structure of MshB from M. tb derived from X-
ray crystallography.  Maynes et al. (2003) deposited the first structure in the Protein Data 
Bank (PDB) at a resolution of 1.70 Å (PDB code 1Q74) in space group P1.  Five days later, 
the second MshB structure was deposited by McCarthy et al. (2004) with a resolution of 
1.90 Å (PDB code 1Q7T) in space group P212121.  These structures showed that MshB is a 
Zn
2+
-dependent metallohydrolase, the N-terminal domain of which resembles the lactate 
dehydrogenase fold while the C-terminal domain has an α/β fold (Figure 1-5).   
 
Figure 1-5: Cartoon representation of MshB (PDB code 1Q7T, chain A). 
The N-terminal domain (red) resembles the lactate dehydrogenase fold while the C-terminal domain (blue) has 
an α/β fold.   
 
The zinc binding site (Maynes et al. 2003) and the mercury binding site (McCarthy et al. 
2004) in both structures is coordinated by His-13, Asp-16 and His-147.  The MshB structure 
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with PDB code 1Q74 shows two water molecules coordinating with the catalytic zinc ion 
(Figure 1-6) and the MshB structure with PDB code 1Q7T shows the fortuitous binding of β-
octyl glucoside (BOG) which is hypothesised to indicate the putative active site due to BOG 
resembling the glucose moiety of the substrate GlcNAc-Ins (Figure 1-7) (McCarthy et al. 
2004).  The binding position of BOG in chain A is hypothesised to more accurately predict 
the binding orientation of the glucose moiety of GlcNAc-Ins.  
 
Figure 1-6: Stereo view of MshB (PDB code 1Q74) showing the zinc ion (grey sphere) and water 
molecules (red spheres) in the putative active site.   
The zinc atom binding site is shown comprising His-13, His-147 and Asp-16.  The carboxyl of Asp-15 is ideally 
positioned to interact with the proposed catalytic water, while the water closest to His-147 is hypothesised to be 
displaced by the substrate upon binding. 
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Figure 1-7: Stereo view of the superimposition of the active sites of MshB (PDB code 1Q7T) showing β-
octyl glucoside. 
The position of β-octyl glucoside (BOG) indicates the putative active site.  Chain A in dark grey and Chain B in 
white.  Asp-95 is on the far left and the zinc atom binding site comprised of His-13, His-147 and Asp-16 are on 
the right.  The BOG binding in chain A is thought to more accurately predict the binding position of the glucose 
moiety of the substrate GlcNAc-Ins. 
 
The catalytic mechanism proposed by Maynes et al. (2003) involves the substrate binding to 
MshB so that the carbonyl oxygen of the acetyl group displaces the water molecule closest to 
His-147 (Figure 1-6) and coordinates with the zinc ion.   
The Asp-15 residue serves as a general base catalyst, assisting the nucleophilic attack of 
water on the amide carbonyl which is polarized by the zinc ion.  The resulting tetrahedral 
transition state would be stabilised by the positively charged zinc ion and the side chain of 
His-144, which is hydrogen bonded to Asp-146.  Finally, the carboxyl group of Asp-15 acts 
as a general acid for the proton transfer to the substrate nitrogen and facilitates the collapse of 
the tetrahedral intermediate with cleavage of the amide bond to leave GlcN-Ins and acetate 
(Figure 1-8).   
His-147 
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Figure 1-8: Schematic of the catalytic mechanism for MshB proposed by Maynes et al. (2003). 
Asp-15 acts as a general base activating a water molecule which then performs a nucleophilic attack on the 
amide carbonyl.  The tetrahedral intermediate is stabilised by the zinc ion and His-144 and collapses, via proton 
transfer from Asp-15 behaving as a general acid, to form GlcN-Ins and acetate. 
 
This mechanism has found wide acceptance (Maynes et al. 2003, Jothivasan and Hamilton 
2008, Newton, Buchmeier & Fahey 2008, Fan et al. 2009).   
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However McCarthy et al. (2004) proposed His-144 to be oriented differently, that the N
ε2
 of 
His-144 would coordinate with the N-acetylglucosamine moeity of the natural substrate 
(Figure 1-9).  The discrepancies in the McCarthy et al. (2004) paper are discussed further on. 
 
Figure 1-9: Comparison between the orientation of His-144 from McCarthy et al. (2004) (a,b,d) and 
Maynes et al (2003) (c). 
The figure in (a) was taken from McCarthy et al. (2004) and shows the modelled orientation of HIS-144 upon 
substrate binding in MshB.  Note the position of the N
ε2
 facing away from the catalytic center and towards O6 
on the BOG moiety found in the active site, in addition note the orientation of His-13 with the N
δ1
 facing 
towards the modeled zinc.  BOG was used to predict the binding of the glucosyl ring of the natural substrate.  
The figure in (b) shows the deposited structure of MshB (with PDB code 1Q7T, Chain A).  Note the His-144 
N
ε2
 facing towards the catalytic center, and the His-13 N
δ1 
facing away from the proposed zinc binding site.  The 
figure in (c) shows the deposited structure of MshB (with PDB code 1Q74, Chain A) in which His-13 was 
modeled with N
δ1
 orientated towards the zinc and with His-144 N
ε2
 facing towards the catalytic center.  The 
histidines in figure in (d) have been re-orientated to match figure (a) for ease of reference with the other figures. 
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The N-acetylglucosamine moiety was modelled on the binding mode observed for β-
octylglucoside (BOG) in the active site of chain A of 1Q7T, which they believed predicted 
the binding of the glucose moiety of the natural substrate, and therefore His-144 could not 
participate in the catalytic mechanism as the nitrogen was not facing the proposed position of 
the amide bond.   
There is a discrepancy in the orientation of His-144 between the description of the crystal 
structure published by McCarthy et al. (2004) with PDB code 1Q7T, and the description of 
the orientation of His-144 when part of the natural substrate (the GlcNAc moiety) was 
modelled into the active site.  In the paper (McCarthy et al. (2004)), His-144 N
ε2
 (Chain A) is 
depicted as being hydrogen bonded to the 6-OH of the glucosyl ring of BOG (with a distance 
of 3.54 Å), in the same orientation as shown in the coordinate file, with N
δ1
 directed towards 
to active site.  However, in the description of the modeling of the GlcNAc moiety into the 
active site, His-144 is oriented differently with N
δ1
 directed away from the active site and N
ε2
 
still hydrogen bonded to the 6-OH of the GlcNAc moiety.  The modelled distance is not 
reported, but if the orientation of His-144 in their deposited structure is changed to match the 
description of binding to GlcNAc, then the distance is approximately 3 Å.  This distance 
would be more favourable energetically.  In addition, His-13 in Chain A of MshB with PDB 
code 1Q7T was modelled with the N
δ1
 facing away from the proposed zinc binding site and 
should be facing towards in order to coordinate the zinc ion.   
Considerable insight into the mechanism was derived from the kinetic experiments of Huang 
and Hernick (2012).  Huang and Hernick (2012) published a paper where mutations in the 
active site of MshB were characterised (Figure 1-10).  The loss of the upper and lower pKa’s 
were noticed when Tyr-142 and Asp-15 were mutated, indicating their importance in the 
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catalytic mechanism.  Based on the structures deposited at the time it was suggested that His-
144 acts as a general acid catalyst and that the N
ε2
 of His-144 was pointed in the direction of, 
and could aid catalysis of, the amide bond of the natural substrate when bound in the active 
site of MshB.  However when His-144 was mutated, the activity was reduced but the pKa’s 
remained largely the same.  Their work also showed that Tyr-142 plays an important role in 
the catalytic mechanism and included Tyr-142 in their schematic (Figure 1-11). 
 
 
Figure 1-10: pH rate profiles figure take from Huang and Hernick (2012). 
The pH dependence of the MshB-catalysed reaction is shown for WT (O), Asp-15 to Ala (   ), Tyr-142 to 
Ala (   ), Tyr-142 to Phe (   ), His-144 to Ala (    ), and Asp-146 to Ala (    ) as described in Huang and Hernick 
(2012). 
 
  
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
39 
 
 
Figure 1-11: Schematic of the catalytic mechanism proposed by Huang and Hernick (2012).   
On binding, Tyr-142 and the catalytic metal polarize the carbonyl group of the substrate.  Asp-15 acts as a 
general base to activate a water for attack on the carbonyl substrate.  The tetrahedral intermediate is stabilised by 
Tyr-142 and the metal ion.  Finally His-144 acts as a general acid to facilitate the breakdown of the tetrahedral 
intermediate. 
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1.9 Homology modeling of Mca 
Homology modeling is a technique used to build a structure of a previously unknown 
molecule based on closely related molecules.  As previously stated, the degree of homology 
between MshB and Mca suggests they could be structurally similar to each other.  Therefore, 
a model of Mca tertiary structure based on the protein sequence of Mca and the structural 
scaffold of MshB could produce a structural model of Mca that might be used to account for 
the differences in substrate specificity between Mca and MshB.   
An attempt to model the first 180 residues of Mca using MshB as a template has been 
published by Maynes et al. (2003), it was reported that the only major difference between the 
two models was that Lys-19 in Mca was found in the location corresponding to Ser-20 in 
MshB.  Maynes et al. (2003) suggested that the glucosyl moiety of GlcNAc-Ins (substrate of 
MshB) could bind in this location and that this difference could cause a steric clash in Mca.  
However MSR (substrate of Mca) has the same glucosyl moiety as GlcNAc-Ins, therefore 
Maynes et al. (2003) believed that either MSR binds in a different orientation or there are 
differences in other parts of the active site that might compensate for the unfavourable 
binding.  For example, residues that bind to the AcCys residue of MSH were hypothesised to 
be Gln-247 and Ser-260, and increased binding affinities here could overcome the steric clash 
introduced by Lys-19.  They were unable to model that region of Mca and therefore were 
unable to comment further.  As mentioned in the previous section however, the structure with 
PDB code 1Q7T was published 5 days later with BOG bound nearer to Asp-95 and His-13.  
This evidence suggested that the glucosyl moiety bound in this region rather than near Lys-
19.  There is a need to build a complete homology model of Mca on the basis of current 
knowledge. 
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1.10 Co-crystallisation of MshB with an inhibitor 
The purpose of co-crystallizing the enzyme with inhibitors is to permit the visualization of 
the interactions between the protein and the inhibitor. The insights obtained from this are 
used to design molecules that satisfy all the criteria necessary for them to be used as drugs 
and still maintain the critical interactions with the enzyme in question. 
Gammon et al. (2010) synthesised 21 substrate analogue inhibitors of the hydrolysis of 
GLcNAc-Ins by MshB and Mca.  Because they were substrate analogues they were proposed 
to act by competitive inhibition.  The most effective inhibitors (Figure 1-12) were found to be 
the thiophenylglycosides (with the thiophenyl group in the same position as the inositol 
moiety, and the glycoside group and amide bond in the same position of that in the natural 
substrate GlcNAc-Ins) linked to plumbagin, and were referred to as compounds VU2-5. 
 
Figure 1-12: General structure of VU inhibitors.   
VU inhibitors (Gammon et al. 2010, Marakalala 2008) are plumbagin linked via 2 to 5 methylene carbons and 
an amide linkage to phenyl-2-deoxy-2-amino-1-thio-α-D-glucopyranoside.  These inhibitors are named VUn, 
with n being the number of carbons in the tether, e.g. for VU5 n=5. 
 
Interestingly the percentage of inhibition was found to be directly related to the length of the 
link, where an increase in the number of carbons in the link increased the amount of 
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inhibition of MshB and Mca activity (Gammon et al. 2010, Marakalala 2008).  VU5, which 
has a five carbon linker, was found to be the most potent inhibitor of MshB and Mca activity. 
For this reason, VU5 was used as the inhibitor for co-crystallisation in this study.  It must be 
noted that no chemical characterisation was reported for VU5 (solubility etc).   
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1.11 Derivitisation of the product of the MshB activity 
assay 
Gammon et al. (2010) derivatised GlcN-Ins, the product of the MshB catalysed deacetylation 
of GlcNAc-Ins, with 6-aminoquinolyl-N-hydroxysuccinamidal carbamate (AccQ-Fluor, 
Waters, USA) using a method published by Anderberg, Newton & Fahey (1998) which 
included visualising the derivatised product using HPLC. 
An alternative method of derivitising the GlcN-Ins product was developed more recently 
using the fluorescent substrate fluorescamine (FSA, Figure 1-13) by Huang and Hernick 
(2011).   
 
Figure 1-13: Chemical structure of fluorescamine and conversion to fluorescent product once the 
fluorescamine molecule had reacted with a primary amine. 
 
FSA only becomes fluorescently active once it has reacted with a primary amine.  The 
amount of fluorescence is thus directly proportional to the amount of free primary amine in 
the solution and can be measured accurately by fluorescent spectrophotometry in a 96 well 
plate.  This method of derivitisation is simple, quick and less costly than other assays using 
AccQ-Fluor.  In short, instead of being based on multiple time-consuming runs on an HPLC 
Fluorescamine Fluorophore 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
44 
 
system, it relies on fluorescent labelling of the primary amine in 96 well plates which are 
easily read on a fluorescent plate reader.   
Another advantage of the Huang and Hernick assay is that the cheaper and commercially 
available substrate analogue GlcNAc was used instead of the natural substrate GlcNAc-Ins 
which is not commercially available and is relatively difficult and expensive to produce.   
Some notable differences between the Gammon et al. (2010) and the Huang and Hernick 
(2011) assays is that Gammon et al. (2010) used half the concentration of Hepes and NaCl, 
and did not include any reducing agent, whereas Huang and Hernick (2011) used 50 mM 
Hepes and 50 mM NaCl, and included 1 mM TCEP to maintain a reducing environment.  The 
assay is described in detail in section 2.5.   
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1.12  Aims and objectives 
The aim of this work, as initially conceived, was the direct visualization of VU5 in the active 
site of MshB by X-ray crystallography. This would then lead to an analysis of the binding of 
this molecule which would be returned to the synthetic chemists for the development of 
further compounds. 
This would be accomplished by: 
 Expression and purification of MshB for use in crystallisation,  
 Co-crystallising the protein with the VU5 inhibitor,  
 Solving the resulting structure by molecular replacement using data obtained from X-
ray diffraction. 
It will be seen that the route to the understanding of VU5 binding was not nearly as 
straightforward as initially conceived and the work outlined above led instead to a new 
understanding of the mechanism of MshB which enables a considerably more insightful 
model of VU5 binding to be built than was previously possible.  
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2 Materials and Methods 
2.1 Expression of recombinant MshB protein in E. coli 
MshB was expressed in E. coli BL21 (DE3) pLysS using a pET17b plasmid.  The E. coli 
carrying the plasmid was a gift from Daniel Steenkamp, Division of Chemical Pathology, 
University of Cape Town.  Colonies were picked, from stock cultures freshly plated on Luria 
Agar (1 % w/v tryptone, 1 % w/v NaCl, 0.5 % yeast extract and 1.5 % agar containing 
100 μg/ml ampicillin and 34 μg/ml chloramphenicol), and inoculated into starter cultures of 
10 ml sterile Luria Broth (LB) (1 % w/v tryptone, 1 % w/v NaCl and 0.5 % yeast extract 
containing 100 μg/ml ampicillin and 34 μg/ml chloramphenicol).  The starter cultures were 
incubated overnight at 37 °C in a shaking incubator.  The 10 ml culture was then added to 1 L 
sterile LB (containing 100 μg/ml ampicillin and 34 μg/ml chloramphenicol) and incubated at 
37 °C in a shaking incubator until the optical density (Absorbance of light with a wavelength 
of 600 nm, OD600nm) reached 0.4-0.6.  Once the cells had reached the appropriate density 
(OD600nm = 0.4-0.6), over-expression of the recombinant protein was induced by the addition 
of isopropyl-1-thio-β-D-galactopyranoside (IPTG) to a final concentration of 0.4 mM and 
incubated overnight at 20 °C in a shaking incubator (100 r.p.m.). 
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2.2 Purification of MshB 
2.2.1 Lysis of MshB-expressing E. coli BL21 cells 
Induced cells were collected by centrifugation at 5 000 x g for 15 min at 4 °C.  The cells were 
resuspended in a total volume of 10 ml lysis buffer (100 mM NaCl, 50 mM Hepes, pH 7.5) 
containing cOmplete
TM
 EDTA-free protease inhibitors (Roche, USA). 
Disruption of the cell membranes was ensured by freezing the cell pellet overnight at -20 °C, 
prior to sonication on ice using a Misonix Sonicator 3 000.  The total sonication process time 
was 4 min at an initial output level of 5 for a sample volume of 10 ml.  Processing was done 
with cycles of 15 s with the pulse on and 15 s with the pulse off.  The insoluble cell debris 
was separated from the soluble cell content by centrifugation at 27 000 x g for 30 min at 
4 °C. 
2.2.2 Ammonium sulphate precipitation 
The supernatant from cell lysate was incubated with 35% ammonium sulphate for one hour at 
4 °C, while being stirred to ensure even distribution and maximum solubility of ammonium 
sulphate in the sample.  The solution was centrifuged at 10 000 x g for 15 min at 4 °C.  The 
supernatant was then removed into a clean tube and the ammonium sulphate concentration 
increased to 55%.  The sample was then incubated for another hour at 4 °C, while being 
stirred.  The 55% solution was centrifuged at 10 000 x g for 15 min at 4 °C. 
The supernatant was removed and the protein pellet from the 55% ammonium sulphate 
sample was resuspended in 50 mM Hepes buffer containing 100 mM NaCl, pH 7.5.  Excess 
ammonium sulphate was removed by dialysis using 10 kDa Snakeskin® molecular weight 
cut-off dialysis tubing (Thermo Scientific, USA), overnight at 4 °C in 2 L 50 mM Hepes 
buffer containing 100 mM NaCl, pH 7.5 while stirring. 
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2.2.3 Anion exchange chromatography 
A Q-Sepharose High Performance (Q-HP) column (GE Healthcare, USA) (column volume of 
30 ml) was used for anion exchange chromatography.  The Q-HP column was prepared and 
washed in the reverse direction of flow with 2 column volumes (CV) 2 M NaCl, followed by 
2 CV distilled water, 2 CV 1 M NaOH and again with 2 CV distilled water.  The column was 
then equilibrated in the normal direction of flow with 5 CV of 50 mM Hepes binding buffer 
containing 100 mM NaCl, pH 7.5.   
The pre-column sample was passed through a 0.45 μm filter and loaded onto the Q-HP 
column at a flow rate of 2.5 ml/min, using a 50 ml superloop injection loop (GE Healthcare, 
USA) in conjunction with a Gilson 321 pump.  The column was then washed with the Hepes 
binding buffer until the optical density stabilised at a baseline value.     
Protein elution was monitored using a Waters 484 tunable absorbance detector (Waters, 
USA; set at 280 nm) and fractions collected using a Gilson FC 204 fraction collector (Gilson, 
USA).   
Bound proteins were eluted by increasing the salt concentration over 10 column volumes 
(CV) using a linear gradient from 100 mM NaCl to 1 M NaCl.  Fractions of 5 ml were 
collected in 60 tubes over 110 min.  The column was finally washed with 5 CV of the Hepes 
elution buffer to ensure that no more protein was bound, and then re-equilibrated with 5 CV 
of the Hepes binding buffer before washing with distilled water and storing in 20 % ethanol.   
The data were transferred to a computer using a Gilson 506C system interface and was 
interpreted using Gilson Unipoint software, version 5.11.   
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2.2.4 Removal of contaminating proteins by size exclusion 
chromatography 
The size exclusion column was packed in-house with Sephacryl™ S300 high resolution 
beads (GE Healthcare, USA) to a column volume of 110 ml with a bed height of 63 cm and 
radius 0.8 cm.  The column was used in conjunction with a Gilson 305 pump (at a flow rate 
of 0.5 ml/min), Gilson 806 manometric module, Gilson UV/Vis-151 absorbance detector (set 
at 280 nm) and a Gilson FC 203B fraction collector (Gilson, USA).  The data were 
transferred to a computer using a Gilson 506C system interface and was interpreted using 
Gilson Unipoint software, version 3.3.   
The column was washed and equilibrated with 2 CV 50 mM Hepes buffer containing 
150 mM NaCl, pH 7.5.  Protein-containing fractions from the Q-HP column were analysed 
by SDS-PAGE; those fractions containing a band of an apparent molecular weight (MW) 
similar to that of the calculated molecular weight of MshB were pooled and concentrated to 
5 ml. The concentrated sample was passed through a 0.2 μm filter to remove particulate 
matter and loaded onto the column.  The proteins were eluted with 2 CV buffer and fractions 
of 0.5 ml were collected in 80 tubes.  Fractions containing putative MshB were pooled and 
concentrated to 4-5 ml which averaged 1 mg/ml protein concentration.   
Protein-containing samples were either stored at 4 °C for use immediately or they were 
diluted with glycerol to a final concentration of 20 %, flash frozen in liquid nitrogen and 
stored at -80 °C.   
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2.2.5 Molecular weight estimation by size exclusion chromatography 
A calibration curve was created by eluting seven standard molecules (Table 2-1) from a 
Sephacryl
TM
 S300 size exclusion column under the same conditions as the experiment.   
Gel filtration molecular weight standards were bought from Bio-rad (USA) and used as per 
manufacturer’s instructions.   
Table 2-1: Table of gel filtration standards 
Standard MW 
Tobacco Mosaic Virus 50000 kDa 
Thyroglobulin 670 kDa 
Gammaglobulin 158 kDa 
Ovalbumin 44 kDa 
Myoglobulin 17.5 kDa 
Vitamin B-12 1.35 kDa 
Acetone 0.58 kDa 
 
The partition coefficient (Kav) is used to compare different sized molecules eluted off a size 
exclusion column by their elution volumes.  It is calculated by subtracting the elution volume 
(Ve) from the void volume (Vo) and then dividing by the internal volume (Vin) (Equation 2.2-
1).   
 
Equation 2.2-1: Equation to calculate Kav for comparing elution volumes of different proteins.  Vo is the 
void volume, Ve is the elution volume and Vin is the internal volume. 
Kav = Vo – Ve / Vin 
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When Kav equals zero, that molecule elutes in the void volume (Ve = Vo).  When Kav equals 
one, that molecule elutes in the internal volume plus the void volume (Ve = Vin + Vo).  For 
very large molecules, the time spent in the internal volume is limited as they cannot fit into 
the pores of the beads and Kav approaches zero.  For very small molecules, the time spent in 
the internal volume is maximised as they can fit into all the pores of the beads and Kav 
approaches one. 
Kav was calculated for each molecule and was plotted against the log of each molecule’s 
molecular weight (logMW), the equation of the resulting straight line was estimated using the 
trendline generated by Excel (Microsoft, USA). 
The molecular weight of MshB was estimated by calculating its Kav value for the 
Sephacryl
TM
 S300 column, and substituting it into the equation from the standard curve 
(Equation 2.2-2). 
Equation 2.2-2: Standard curve equation from S300 molecular weight standards.   
LogMW = -4.4Kav + 6.5 
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2.2.6 Concentration of protein samples 
Protein samples were concentrated using a stirred cell filtration unit (Amicon, USA) with a 
10 kDa molecular weight cut-off ultra filtration membrane (Amicon, USA) at 4 °C.   
2.2.7 Protein concentration determination 
Protein concentration was determined using a Bradford protein assay (Bio-Rad, USA).  The 
assay was performed as instructed in the manufacturer’s manual.  Bovine serum albumin was 
used as the standard in 0.1 mg/ml increments from 0.1 mg/ml to 0.5 mg/ml (Figure 2-1).   
 
 
Figure 2-1: BSA standard curve. 
The Bradford standard curve was made using BSA concentrations ranging from 0.1 to 
0.5 mg/ml in 0.1 mg/ml increments.  The resulting equation used for converting absorbance 
units to concentration (mg/ml) is presented on the graph.  Measurements were performed in 
triplicate and the y-axis error bars are shown on the graph. 
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2.2.8 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Sample purity and protein size was estimated using 16 % or 20 % SDS-PAGE stained with 
Coomassie Brilliant Blue R-250 as per the standard protocol (Laemmli 1970).  Pageruler ™ 
prestained protein ladder and prestained protein ladder plus (Fermentas, Canada) were used 
as the molecular markers with 5 ul being loaded on the gel.  Samples were prepared by 
mixing 5 ul of 4x sample application buffer (SAB) (200 mM Tris-HCl pH 6.8, 8 % SDS, 
40 % glycerol, 4 % β-mercaptoethanol, 50 mM EDTA and 0.08 % bromophenol blue) with 
15 ul sample and boiled for five minutes to ensure that the proteins were sufficiently 
denatured.  Depending on the protein concentration of the sample, 5 – 20 ul were loaded onto 
the gel.  The gels were run for 90 min at 10 mA in running buffer (0.025 M Tris-HCl, 
0.192 M glycine, 0.1 % SDS, pH 8.3). 
2.2.9 Protein Purity Estimation 
Protein purity was estimated by densitometry using the computer program ImageLab (Bio-
Rad) (Appendix A).  SDS-PAGE analysis was carried out on samples from S300 size 
exclusion chromatography experiments and subsequently analysed with ImageLab.  Lanes 
were created manually, while the bands were first detected automatically using the high 
sensitivity setting and then manually adjusted as necessary. 
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2.3 X-ray Crystallography 
2.3.1 Crystallisation 
Protein crystallisation refers to the technique where molecules in solution are allowed to 
precipitate out of solution slowly in a controlled manner creating a crystalline solid that 
produces an X-ray diffraction pattern.  The most common way of achieving this is by forcing 
the effective concentration of the enzyme to increase in a slow, controlled manner.  This can 
be done by regulating the evaporation of the solvent which in turn increases the concentration 
of the enzyme and other molecules in the solution that act as precipitants.  The protein 
effectively reaches a supersaturated stage and once nuclei form, crystal growth can be 
achieved.  Nuclei can take the form of anything present in the solution that initiates crystal 
formation.  Crystals have to be grown until they are at least big enough to be hit with the X-
ray beam.  Bigger crystals with good long-range order will give better signal-to-noise ratios 
when compared to smaller crystals or crystals with poor long range order; it is therefore 
easier to obtain higher quality data from large, well-ordered crystals.   
There are various crystallisation techniques; including batch crystallisation, liquid-liquid 
diffusion, hanging drop vapour diffusion, sitting drop vapour diffusion and dialysis; that 
crystallographers use to control precipitation conditions and induce crystal growth.  In this 
study, the hanging drop vapour diffusion method was used to grow crystals (Jan Drenth 
1999).  Figure 2-2 is a simplified phase diagram used to explain the process of protein 
crystallisation with respect to protein and precipitant concentration.   
Hanging drop vapour diffusion involves suspending a one-to-one solution of protein to 
precipitant solution on a cover slip over a well of concentrated precipitant.  The well is sealed 
and the protein/precipitant solution is allowed to equilibrate with the precipitant in the well 
by evaporation (Figure 2-3).  
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
55 
 
 
Figure 2-2: Simplified phase diagram for protein crystallisation.  
Paths for batch (A), hanging/sitting drop vapour diffusion (B), dialysis (C), and liquid-liquid diffusion (D) are 
shown.  Crystals only form in the zone of supersaturation (right of the solubility curve), where the concentration 
of the protein in the precipitant solution is above its solubility. In the zone of undersaturation (left of the 
solubility curve), crystals dissolve and cannot form. The metastable zone indicates conditions where crystals are 
stable and will not dissolve.  In the zone of precipitation protein will precipitate in an unordered fashion.  The 
zone of nucleation indicates the conditions where nucleation can occur thus initiating crystal growth (Figure and 
caption from Li and Ismagilov (Li, Ismagilov 2010) International Union of Crystallography©. 
 
 
Figure 2-3: Hanging drop vapour diffusion 
Hanging drop vapour diffusion involves suspending a solution of protein to precipitant (where the concentration 
of precipitant does not immediately cause precipitation) on a cover slip over a reservoir of concentrated 
precipitant.  The well is sealed and the protein/precipitant solution is allowed to equilibrate by diffusion of water 
from the droplet to the reservoir.  This results in the concentration of the precipitant causing crystal formation.  
protein/precipitant mixture 
cover slip 
Precipitant reservoir 
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Protein crystallisation is a process involving many variables.  In order to reduce these 
variables to a manageable number of conditions, it is common to use “sparse matrix” 
screening, i.e. a process of trial and error covering a wide range of different conditions.  The 
phase diagram (Figure 2-2) shows how the protein and precipitant concentration affect 
protein solubility and illustrates how, over time, the concentration of protein changes during a 
crystallisation experiment.  To grow crystals, conditions need to pass through the 
supersaturated zone and into the nucleation zone, without forming a precipitate.  Once 
nucleation is achieved, the protein crystals should start growing and cause the concentration 
of protein to drop (Figure 2-2).  A large number of diverse conditions need to be screened 
before the search can be narrowed to the optimum conditions.  Once hits are obtained, 
conditions are optimised to improve the rate at which crystal growth occurs and improve the 
size of the crystals.  These include changes to the concentration of the precipitant, the pH, the 
temperature and the starting concentration of the protein. 
Alterations to the concentration of precipitant and protein have obvious consequences, as 
increasing the concentration of either will increase the rate of precipitation.  Changing the pH 
of the solution alters the charges on the molecules that are present in solution, and thus 
changes the repulsion or attraction between molecules.  Changing the temperature may either 
increase or decrease the solubility of the protein. 
Prior to crystallisation attempts in this study, the protein solution was dialysed against 50 mM 
Hepes buffer, pH 7.5, overnight at 4 °C to reduce the salt concentration.  MshB was 
incubated with a 5 times greater molar concentration of the VU5 inhibitor at 4 °C for 30 min 
before setting up the crystal trials.  The stock concentration of MshB was approximately 
19 mg/ml and was diluted as necessary during the optimisation procedure. 
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2.3.2 Identifying crystallising conditions for MshB 
Initial crystallisation hits were identified using the Hampton crystal screen and PEG/ion 
screen kits (Hampton Research, USA).  Equal volumes of protein and precipitant solution 
from the screening kits (2 μl each) were mixed on a cover slip and inverted and sealed with 
vacuum grease over 1 ml reservoir solution as per the hanging drop vapour diffusion method 
(Drenth, 1999).  Protein samples were centrifuged at 5 000 x g for 1 min and filtered through 
a 0.2 μm filter prior to all crystallisation attempts.  All crystallisation attempts were incubated 
at 22 °C and monitored daily.  Hits were identified as those conditions that at best gave small 
crystals, or at worst formed a precipitate over the period of a week. 
2.3.3 Optimisation of crystallisation conditions for MshB 
Once conditions are found that show signs of precipitation, nucleation or crystal formation, 
the conditions around these hits are explored by altering the pH, precipitant concentration, 
protein concentration and temperature.  The phase diagram shows how conditions that form 
precipitates can be considered as hits.  If the precipitating factors in these conditions are 
decreased, the experiment can enter the nucleation zone before forming precipitate and can 
potentially form crystals instead.  These optimisations are usually done using hanging or 
sitting drop methods as they can accommodate higher volumes and therefore bigger crystals.  
Once the optimum conditions have been found, crystallisation can be optimised further by 
methods such as streak seeding and macro seeding.  Seeding is used to try control the number 
of nucleation sites.  Streak seeding involves crushing or stroking existing crystals with a 
seeding tool so that shards of crystals get stuck to the seeding tool.  Subsequently the seeding 
tool is rinsed to get rid of excess crystal shards so that only a few nucleation sites are 
introduced in an attempt to obtain a few large crystals rather than many small crystals. The 
seeding tool is then dragged through a drop of protein/precipitant mixture that has been 
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allowed to equilibrate for an hour, after which the drops are returned to their wells and 
allowed to equilibrate further.  The few crystal shards that fall off into the protein/precipitant 
solution then act as nucleation sites in the equilibrated supersaturated drops and hopefully 
form a few large, good-quality crystals (Figure 2-4). 
 
Figure 2-4: Crystals forming along a streak line after streak seeding.   
Micrograph of Haemophilus influenzae hypothetical protein HI1161 crystals produced by streak seeding 
homologous protein through equilibrated drops prior to using the hanging drop vapour diffusion method 
(Georgiev et al. 2006). 
 
Hits were optimised in this study by varying the precipitant concentration, the pH and/or the 
protein concentration.  Protein concentration was varied from 0.5 – 7 mg/ml by diluting the 
stock protein appropriately with 50 mM Hepes buffer, pH 7.5.  Protein and precipitant 
concentration were varied by diluting the hanging drops.  This was achieved by the addition 
of 50 mM Hepes buffer, pH 7.5 in 0.5 µl increments, effectively diluting the precipitant and 
protein by 11% when 0.5 μl was added, 20% when 1 µl was added, 27% when 1.5 μl was 
added, and 33% when 2 μl was added.  
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2.3.4 Optimising crystal growth for MshB crystals 
Crystal growth was optimised by micro-seeding existing MshB crystals into hanging drops 
that had been pre-equilibrated for 1 hour (homologous seeding).  A home-made micro-
seeding tool (human eyelash) was brushed against an existing crystal, washed in buffer 
(50 mM Hepes buffer, pH 7.5) to remove excess crystal shards, and subsequently drawn 
through the pre-equilibrated drops.  The micro-seeding tool was washed in distilled water 
(dH2O) and dried between successive micro-seeding attempts. 
2.3.5 Preparation of MshB crystals for transport and X-ray diffraction 
For X-ray data collection, crystals need to be transferred into a loop of nylon that is 
approximately the same size as the crystal and fixed onto a metal capillary that can be 
attached to the goniometer head.  The goniometer is the device that alters the angle of 
presentation of the crystal to the X-ray beam in the diffractometer.  To try to stabilise the 
crystal and also limit the damage caused by the X-ray beam, the crystals are soaked briefly in 
a cryo-protectant and then flash-frozen in liquid nitrogen.  Freezing prevents evaporation of 
the solvent, which is important in stabilising the protein because solvent channels make up 
about 40-60 % of a crystal’s volume; if the solvent were to evaporate, the crystal can collapse 
and be destroyed.  The decrease in temperature also minimizes the vibrational energy of the 
atoms which can enhance the diffraction pattern.  The cryo-protection and flash freezing are 
done to prevent ice crystals from forming, as ice crystals destroy the protein crystals and 
produce diffraction rings which can obscure data originating from the protein crystal.  It is 
important to move the crystal through the air above the liquid nitrogen as fast as possible; the 
layer of cold air/evaporated nitrogen can start the cooling and freezing process which can 
complicate flash freezing (Rhodes, 2006). 
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Prior to storage in liquid nitrogen and subsequent transport to the beam-line, MshB crystals 
were mounted on a nylon loop and soaked in cryo-protectant (precipitant solution diluted to 
20 % glycerol) for 10 seconds prior to being flash frozen in liquid nitrogen. 
2.3.6 X-ray diffraction, model building and model refinement of MshB 
Figure 2-5 provides an overview of the steps required to produce a protein structure from a 
protein crystal.  Diffraction data were collected at beam-line BM14 at the European 
Synchrotron Radiation Facility (ESRF), Grenoble, France.  Collecting data on a synchrotron 
has an advantage over home sources because of the increased beam intensity.  BM14 also has 
an advantage in that data collection is highly automated.  Data frames in this study were 
collected at one degree oscillations over a range of 180 °, under a stream of nitrogen vapour 
at a temperature of 100 K.  The exposure time for each frame was 20 s and each frame was 
collected on a MAR225 CCD detector. 
 
Figure 2-5: This chart describes the steps required to solve a structure from a crystal. 
 
Mount crystal 
Collect a few frames of 
data 
Determine laue group 
and unit cell 
dimensions 
Program data collection 
strategy 
Collect data 
Integrate diffraction 
spot intensities (XDS) 
Scale and merge data 
from the frames 
collected (XDS) 
Determine structure 
using molecular 
replacement (Phaser) 
Display structure and 
map and interactively 
modify model on the 
basis of the map (Coot) 
Refine structure 
(Refmac5, Phenix) 
Add water, ligands,etc 
(Coot) 
Cycle last three steps to 
reiterately refine the 
structure 
Analyse structure 
Fix outliers 
Refine 
Final co-ordinates of 
protein structure 
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XDS (Kabsch, 2010) is one of many programs that are used for partially automated indexing, 
integration, scaling and refinement.  First the crystal properties must be determined and 
refined by indexing and integration.  The detector and experimental properties are entered in 
manually after which the program finds (and refines) the reflections (from two image frames 
90° apart) and determines the unit cell dimensions and tries to work out the crystal symmetry, 
orientation and space group.  Knowing these crystal parameters, the program can predict 
where reflections will be on each data frame, and which reflections will span more than one 
frame.  Integration of the data provides three dimensional profiles from predicted reflection 
positions which XDS (Kabsch, 2010) uses to re-refine the crystal properties by minimizing 
the differences between the observed and calculated positions of the reflections.  The data are 
then scaled so that symmetry related reflections throughout the dataset are of the same 
intensity and the reflections are corrected for absorbance by the crystal and surrounding 
mother liquor. 
Phaser (McCoy et al. 2007) is one of several available programs for solving X-ray data and 
forms part of a suite of programs in CCP4 (Collaborative Computational Project number four, 
1994).  The advantage of Phaser is that it is highly automated and the steps involved in 
molecular replacement require very little user input.  Phaser uses Patterson functions to 
determine the correct orientation of the model by first investigating the cross-rotation and 
then the cross-translation functions.  The program then calculates the phases derived from the 
structural model which has been placed in the correct orientation.  Patterson functions can be 
derived directly from amplitude data without phases; this is advantageous because during the 
collection of X-ray crystallographic data, the phase information is lost. 
Like Phaser, Refmac (Murshudov, Vagin & Dodson 1997) is also part of the CCP4 suite.  
Refmac optimises the correspondence between the measured and calculated diffraction 
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intensities subject to restraints that the bond angles and bond distances should be correct.  
PHENIX (Adams et al 2010) was also used to refine bond angles and bond distances. 
In short, the data were integrated, scaled and averaged using XDS (Kabsch, 2010), the phases 
were calculated using Phaser_MR (McCoy et al. 2007) and refined using Refmac_5 
(Murshudov, Vagin & Dodson 1997) and PHENIX (Adams et al 2010) in conjunction with 
manual model-building using Coot V0.6.1 (Emsley et al. 2010) while 5 % of the data were 
kept aside to calculate R-free; model refinement was stopped when R-free stopped 
decreasing.  The initial model used for calculating the phases was chain B of MshB from 
PDB entry 1Q7T (McCarthy et al. 2004).  Molecular graphics were visualised using Chimera 
V1.5 (Pettersen et al. 2004).   
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2.4 Modeling of Mca 
Homology modeling of Mca based in the structure of MshB determined in this dissertation 
was carried out using Modeller 9v8 (Sali, Blundell 1994) and the model with the lowest 
zDOPE score was chosen.  zDOPE stands for a normalised Discrete Optimized Protein 
Energy (DOPE), which is an atomic distance-dependent statistical score where negative 
values indicate better models (Shen, Sali 2006).  The Mca amino acid sequence was 
submitted to GenThreader (Lobley, Sadowski & Jones 2009); the highest score was an 
alignment with chain A of MshB with PDB code 1Q74 (Figure 3-20).  The structure of MshB 
that was solved in this study (Figure 3-13) was used as the reference structure.  The Mca 
secondary structural elements were constrained to those predicted by Psipred (Buchan et al. 
2010) (Figure 3-21).  CastP (Dundas et al. 2006), a program that analyses pockets, was used 
to compare the pockets found in the MshB structure solved here and those found in the Mca 
structure modelled here.  A web based server, ProSA-web (Sippl, 1993, Weiderstein, Sippl, 
2007), was used to validate the model generated by Modeller.  The ProSA-web server 
provides an overall z-score which indicates overall model quality, and an energy plot which 
shows local model quality.  The z-score is compared to z-scores of all deposited protein 
structures in the Protein Data Bank (PDB), therefore an acceptable z-score is one that falls 
within the range of z-scores found in the PDB.  The energy associated with the amino acid 
sequence is acceptable if it shows negative values, and positive values show parts of the 
model that could be problematic (Weiderstein, Sippl, 2007). 
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2.5 Characterisation of MshB Activity 
All plots were derived from experiments that were performed in triplicate and the standard 
deviation from the mean is shown using y-axis error bars.  Where the errors bars cannot be 
seen, they are hidden by the size of the marker. 
2.5.1 MshB activity assays 
MshB activity was assayed with GlcNAc (N-acetyl Glucosamine) using an assay adapted 
from Huang and Hernick (2011).   
Various concentrations of substrate (0, 5, 25, 50, 100, 150 and 200 mM GlcNAc) were made 
up to 1.5 ml in 50 mM Hepes buffer with 50 mM NaCl and 10 mM dithiothreitol (DTT), 
pH 7.5, and incubated in a 37 °C water bath prior to starting the reaction by the addition of 
enzyme at 1 µM final concentration.   
Each reaction was performed in triplicate in 2 ml Eppendorf tubes.  The Eppendorf tubes 
were vortexed before each time point was taken (0, 10, 20, 30, 40, 50 and 60 min).  The 
reaction was stopped by removing a 200 µl sample and incubating it with 70 µl 20 % tri-
chloro acetic acid (TCA) for 10 min in a 96 well plate.  The pH was returned to neutral by 
removing a 25 µl sample into 75 µl 1 M sodium borate buffer, pH 9.0 in a separate 96 well 
plate.  Once all time points were transferred into borate buffer they were derivatised with 
30 µl 10 mM FSA (in acetonitrile) and incubated for 10 min at room temperature.  
Fluorescence was measured on a Cary Eclipse Fluorescence Spectrophotometer (Varian, 
Australia) using an excitation wavelength of 390 nm and an emission wavelength of 475 nm 
(Huang, Hernick 2011).  The rate of GlcN produced was plotted and the initial rates were 
found using the linear portion of the graphs which corresponded to the 0-30 min time points. 
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2.5.2 Effect of DTT and VU5 on MshB activity assayed with GlcNAc 
substrate 
The possibility of DTT inhibiting MshB activity was investigated by increasing the DTT 
concentration from 10 mM to 100 mM. 
Additionally, the effect of VU5 on the activity of MshB alone and MshB with GlcNAc was 
investigated using various concentrations of VU5, 0.1, 1 and 5 mM in the presence of 10 mM 
and 100 mM DTT. 
2.5.3 Graphics and structural analysis 
Images of small molecules and mechanism pictures were re-drawn in Accelrys Draw 
(Accelrys 2011).  Chimera V1.5 was used for structural analysis including alignment of 
protein molecules and hydrogen bond prediction (Pettersen et al. 2004).   
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3 Results 
3.1 Protein expression 
In order to obtain sufficient amounts of protein for crystallisation and activity assays, MshB 
was recombinantly expressed in E. coli.   
Cells were grown to an OD600 of 0.4-0.6 at which time an uninduced sample was removed 
and recombinant expression of MshB was induced by the addition of IPTG.  The cells were 
left to express overnight and another sample was removed.  The two samples were analysed 
using SDS-PAGE (Figure 3-1).  After comparison of the total protein content in the cells pre- 
and post- induction, protein with an apparent molecular weight of 33kDa (corresponding to 
the calculated MW of MshB) was found to be over-expressed after overnight induction.  The 
recombinant method of over-expression yielded sufficient MshB protein to carry on with 
purification. 
 
Figure 3-1: 20 % SDS-PAGE showing expression of MshB 
Protein with an apparent MW of 33 kDa, corresponding to the calculated MW of MshB was found to be over-
expressed in the IPTG induced fraction.   
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3.2 Protein purification scheme 
3.2.1 Purification scheme overview 
 
Figure 3-2: Purification scheme overview 
Flow diagram giving a basic overview of the steps involved in purification of MshB in this study (Blue blocks).  
The final block in the scheme shows the different uses of the purified protein samples (Red block).  Each time 
MshB was purified, the procedure was carried out in full (I.E. each step was carried sequentially and once only, 
per round of purification). 
 
The soluble fraction of whole cell lysate was subjected to ammonium sulphate precipitation.  
The 35-55 % ammonium sulphate cut subjected to anion exchange chromatography and 
finally, the fractions containing MshB were passed through a size exclusion column to further 
improve purity and to examine potential oligomerisation. 
The results that follow are representative of different repeated steps of a single purification 
scheme. 
Whole cell lysate 
Ammonium sulphate 
precipitation 
Anion exchange 
chromatography 
Size exclusion 
chromatography 
Crystallisation, 
Assays & Storage 
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3.2.2 Ammonium sulphate precipitation 
After overnight expression the cells were lysed by sonication and the soluble cell content was 
separated from the insoluble cell content by centrifugation.  Ammonium sulphate 
precipitation was carried out on the soluble cell content as the first purification step in order 
to remove as many contaminating proteins as possible before performing anion exchange 
chromatography.  This was done to improve the efficiency of the anion exchange step.   
Initially a range of ammonium sulphate cuts were performed to investigate the appropriate 
percentage of ammonium sulphate that gave the best separation of putative MshB from 
contaminating E.coli proteins.  Soluble cell content was sequentially incubated with 
increasing percentages of ammonium sulphate, after each increase the precipitated protein 
was removed and resuspended in 50 mM Hepes buffer containing 100 mM NaCl, pH 7.5 for 
analysis by SDS-PAGE.  The best separation was found to be given by a 35-55 % ammonium 
sulphate cut of the soluble cell content.  The following result (Figure 3-3) shows 
representative analysis of subsequent experiments where the soluble cell content was 
subjected to 35 % ammonium sulphate precipitation, after which the supernatant fraction 
(SNF) was removed and subjected to 55 % ammonium sulphate precipitation.   
SDS-PAGE revealed the presence of a band indicating over-expressed protein with an 
apparent molecular weight similar to that of the calculated molecular weight of MshB in the 
soluble cell content and in the resuspended 35-55 % ammonium sulphate cut.  The 35-55 % 
ammonium sulphate precipitation cut successfully separated the putative MshB from many 
contaminating proteins (lane 8 Figure 3-3) and was dialysed, centrifuged and filtered prior to 
anion exchange chromatography. 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
69 
 
 
Figure 3-3: 16 % SDS-PAGE of ammonium sulphate precipit tion steps 
The band corresponding to MshB is indicated.  Ammonium sulphate precipitation was effective in removing 
some contaminating E.coli proteins as can be seen by comparing lane 4 with lane 8.   
 
3.2.3 Anion exchange chromatography 
Anion exchange chromatography was used in an attempt to further separate MshB from 
contaminating E.coli proteins.  In order to optimise the purification of MshB, multiple 
attempts with various techniques were employed.  In the first round of purification the 
ammonium sulphate precipitation step was not included, and will be discussed first.   
Soluble cell content obtained from E.coli that was induced to express putative MshB 
overnight was filtered and loaded onto a QHP anion exchange column with a column volume 
(CV) of 30 ml.  The column was pre equilibrated with 50 mM Hepes binding buffer 
containing 100 mM NaCl, pH 7.5.  Proteins were eluted in 5 ml fractions using a linear 
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gradient of NaCl from 100 mM to 1 M over 10 column volumes (CV) at a flow rate of 
2.5 ml/min.   
Figure 3-4 shows the resulting chromatogram and corresponding SDS-PAGE analyzing 
column fractions.  Many protein peaks eluted from the Q-HP column, with the first three 
separating well from other peaks while the remaining peaks were overlapping with other 
peaks.   
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(a) 
 
(b) 
 
 
  
 
Figure 3-4: Analysis of soluble cell content eluted off an anion exchange column. 
(a) Chromatogram of soluble cell content eluted off an anion exchange column.  Peaks are labeled according to 
elution time.   
(b) Analysis by SDS-PAGE found that MshB eluted at 36 minutes (lane 6) and that a considerable amount of 
MshB was seen in the flow through fraction (lane 19).  The volume of the flow through was 200 ml.  Bands 
corresponding to MshB are labeled with an arrow. 
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Analysis of the fractions by SDS-PAGE (Figure 3-4) revealed that the fractions containing 
MshB eluted off the column in a discrete peak at 36 min.  This showed that anion exchange 
chromatography was effective in separating putative MshB from the majority of E.coli 
contaminating proteins. 
It was noticed however that the flow through (FT) contained a significant amount of putative 
MshB (Figure 3-4 (b), lane 19).  To investigate whether this putative MshB was not binding 
to the column due to it being outcompeted by E.coli proteins or if the putative MshB was just 
not interacting with the column for some reason, the flow through was re-loaded onto the 
column and the resulting chromatogram is shown in Figure 3-5. 
 
Figure 3-5: Chromatogram of the FT from the previous run, eluted from Q-HP. 
The peak corresponding to MshB eluted off the column at 38 min. 
 
SDS-PAGE analysis of column fractions (Figure 3-5) showed that MshB eluted at 38 min.  
This result suggested that removal of contaminating proteins might improve the performance 
of anion exchange chromatography.  For this reason ammonium sulphate precipitation was 
included as a purification step prior to anion exchange chromatography in subsequent 
purification attempts.   
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Figure 3-6 is a representative chromatogram of anion exchange chromatography of the 
soluble cell content after ammonium sulphate precipitation.  The chromatogram shows fewer 
peaks when compared to Figure 3-4 (a) and the MshB containing peak at 36 min 
(corresponding to fraction 19 & 20) was well resolved after the inclusion of the ammonium 
sulphate precipitation step prior to anion exchange chromatography.   
Figure 3-7 is a representative SDS-PAGE analysis of subsequent purifications where an 
ammonium sulphate precipitation step (Figure 3-3) was included prior to elution from the Q-
HP column.   
 
 
Figure 3-6: Representative chromatogram of anion exchange chromatography of the soluble cell content 
after ammonium sulphate precipitation.   
MshB eluted off the column at 36 min and was well separated from the other peaks present on the 
chromatogram.  The apex of the peak was split over two fractions, 19 and 20. 
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16 % SDS-PAGE analysis of representative samples from ammonium sulphate precipitation and subsequent Q-
HP anion exchange chromatography steps.  The bands corresponding to MshB are labeled with an arrow.  It is 
important to note that there are still some high MW contaminants present.  The QHP fractions 19 and 20 
constituted the protein-containing peak at 36 min in Figure 3-6 
 
There were still high MW contaminating proteins in the MshB containing fractions after 
anion exchange chromatography (Figure 3-7, lane 9 & 10), therefore these fractions were 
pooled and concentrated and subjected to size exclusion chromatography.  . 
  
Figure 3-7: SDS-PAGE analysis of MshB purification by ammonium sulphate precipitation followed by 
anion exchange chromatography. 
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3.2.4 SephacrylTM S300 calibration 
Size exclusion chromatography (SEC) was used as the final purification step, apart from 
removing high MW contaminants from the MshB containing sample, SEC allows estimation 
of the molecular weight and investigation of the possibility of quaternary structure.   
Molecular weight standards were eluted from the Sephacryl
TM
 S300 column under identical 
conditions to those of the MshB elution (Figure 3-8).  That is, Sephacryl
TM
 S300 was packed 
in house to a column volume of 110 ml.  0.5 ml fractions were collected over 2 column 
volumes at a flow rate of 0.5 ml/min with 50 mM Hepes buffer containing 150 mM NaCl, pH 
7.5.    
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(a) 
Standard MW Label on chromatogram Elution time 
Tobacco Mosaic Virus 50000 kDa 1 107 min 
Thyroglobulin 670 kDa 2 120 min 
Gammaglobulin 158 kDa 3 157 min 
Ovalbumin 44 kDa 4 174 min 
Myoglobulin 17.5 kDa 5 197 min 
Vitamin B-12 1.35 kDa 6 239 min 
Acetone 0.58 kDa 7 263 min 
 
(b) 
 
Figure 3-8: Calibration of the Sephacryl
TM
 S300 column 
(a) Table of protein standards used in the Sephacryl
TM
 S300 size exclusion column calibration showing their 
respective molecular weights, elution time and label on chromatogram. 
(b) Chromatogram of protein standards passed through the Sephacryl
TM
 S300 size exclusion column. 
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The apex of the peaks corresponding to the size exclusion chromatography MW standards 
were separated by the Sephacryl
TM
 S300 column, however many of the sides of the peaks 
were overlapping and therefore poorly resolved.  Despite this, the column should still be able 
to separate putative MshB (33 kDa) from high MW contaminants visible in Figure 3-7.  The 
calibration curve was calculated by plotting the LogMW of the standards against their 
partition coefficient (Figure 3-9). 
 
Figure 3-9: Sephacryl
TM
 S300 Calibration curve 
This curve was plotted using data obtained in Figure 3-8 The higher MW proteins have a partition coefficient 
tending towards 0 while the lower MW proteins have a partition coefficient tending towards 1 as expected. 
 
3.2.5 SephacrylTM S300 Size exclusion chromatography of the MshB 
containing fractions 
Fractions containing MshB from the anion exchange run were pooled, concentrated, filtered 
and loaded as an individual 5 ml sample onto the Sephacryl
TM
 S300 size exclusion column 
and were eluted under identical conditions to those of the size exclusion standards (Figure 
3-10).   
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  (a) 
 
 
Figure 3-10: Sephacryl
TM
 S300 Size exclusion analysis 
(a) The chromatogram shows one major peak at 173 min.  (b) SDS-PAGE analysis of this peak shows MshB 
indicated by an arrow, and persistent high molecular weight contaminants. 
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Figure 3-10 shows that a major peak eluted at 173min.  SDS PAGE analysis of this peak 
indicated that the majority of the protein corresponded to MshB.  The peak seemed well 
resolved, although small amounts of high MW contaminants were present when the fractions 
were analysed by SDS-PAGE.   
The estimated molecular weight of the putative MshB was calculated to be 46 kDa using the 
Kav value obtained from the size exclusion experiment, and the equation calculated from the 
calibration curve (Figure 3-9).  Even though the calculated MW is higher than the published 
MW of approximately 33 kDa, this is most likely due to a lack of sensitivity as the peaks on 
the chromatogram of the SEC standards (Figure 3-8) are not well resolved and the least 
squares regression analysis of the calibration curve falls below the molecular weight 
standards used that represent 44 and 17.5 kDa (Figure 3-9).  MshB most likely elutes as a 
monomer as there is no evidence that indicates dimer formation, although in future a 
thorough investigation should be performed to confirm this. 
Size exclusion chromatography did not significantly separate MshB from high MW 
contaminants.   
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3.2.6 Purification table 
A purification table (Table3-1) was drawn up based on specific activity determined by 
activity assays using GlcNAc as a substrate and the total protein concentration determined by 
a Bradford assay calibrated using BSA (Figure 2-1).  The purification table shows that a large 
proportion of MshB activity was retained over the duration of purification, with a purification 
factor of over 70 fold and a final yield of over 70 %.  The pooled and concentrated  S300 
protein containing fractions were used in all further crystallography trials and enzyme assays 
as these samples were deemed to be the most pure.  Protein purity was estimated by 
densitometry using the computer program ImageLab (Bio-Rad).  An SDS-PAGE analysis 
was carried out on the protein containing fractions from S300 Size Exclusion 
Chromatography elution (four fractions centred on the peak of the resulting S300 
chromatogram) and subsequently analysed with ImageLab (Appendix A).  The average purity 
of the band corresponding to the estimated MW of MshB in each lane was estimated to be 
almost 85 %. 
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Table3-1: MshB purification table 
Sample 
protein 
concentration 
Total 
volume 
Total 
protein 
Activity 
units 
Total 
activity 
Specific 
activity Yield 
Purification 
factor 
  (mg/ml) (ml) (mg) (mM/min) (units.ml) (mM/min/mg) (%)   
Soluble cell 
content 7.29 17.0 123.96 5.50E-03 9.35E-02 4.44E-05 100.00 1.00 
55% pellet 
sample from 
ammonium 
sulphate 
precipitation 1.79 16.0 28.60 5.80E-03 9.28E-02 2.03E-04 99.25 4.57 
Fraction #19 
from Q-HP 1.11 5.0 5.54 1.24E-02 6.20E-02 2.24E-03 66.31 50.44 
Fraction #20 
from Q-HP 0.98 5.0 4.88 2.26E-02 1.13E-01 4.63E-03 120.86a 104.31a 
S300 protein 
containing 
fractions, 
pooled and 
concentrated 1.04 4.5 4.66 1.50E-02 6.75E-02 3.22E-03 72.19 72.49 
 
The value designated by “a” in Table3-1 seems unlikely at first glance but could be explained 
by the possibility that partial separation of active and inactive MshB provided an artificially 
increased specific activity in fraction 20, this produced artificially increased yield and 
purification factor results. 
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3.3 X-ray Crystallography of MshB crystals 
An attempt was made to co-crystallise purified MshB (MshB containing fractions that were 
pooled and concentrated after S300 Size Exclusion Chromatography during this study, and 
MshB containing samples that were stored frozen by Dr Marakalala (2008)) with VU5 in 
order to investigate the crystal structure with a bound inhibitor. 
3.3.1 Identifying and optimising crystallizing conditions 
Purified MshB protein was incubated with 5 times molar concentration of VU5 and 
subsequently used in crystallisation trials using the hanging drop method with the Hampton 
crystal screen and PEG/ion screen kits.  The VU5 and MshB sample was mixed 1:1 with 
mother liquor on a cover slip and allowed to equilibrate until crystals were noticed in the 
hanging drop.  The conditions that provided crystals were optimised by altering the pH and 
protein concentration.  Crystals that were grown were then used to streak seed the most 
promising conditions that were identified after optimisation.  Figure 3-11 shows crystals that 
were grown and used to obtain diffraction data. 
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Figure 3-11: MshB crystals grown after streak seeding  
A pre-equilibrated hanging drop containing MshB (pre-incubated with VU5) and mother liquor was streak 
seeded with MshB micro crystals and allowed to equilibrate further at room temperature. 
 
Crystals were found to grow best overnight in mother liquor containing 0.1 M sodium 
acetate, 0.2M ammonium sulphate, 25% PEG 4000, pH 4.6, that had been diluted 1:1 with 
4 mg/ml MshB (purified in this study and pre-incubated for 30 min with 5 times molar 
concentration of VU5 i.e. approximately 500 µM VU5) in 50 mM Hepes pH 7.5 and streak 
seeded with micro crystals (initial crystals were made using MshB purified by Dr Marakalala 
(2008)), using hanging drop vapour diffusion.  Approximate crystal dimensions were 0.2 mm 
x 0.25 mm x 0.1 mm (Figure 3-11).   
The protein material used to make crystal seeds was material that had been expressed, 
purified and stored at -80 °C in 20 % glycerol by Dr Marakalala during his PhD (Marakalala 
2008).  This material was used (as opposed to material produced during this study) because 
the material produced in this study failed to form crystals without the help of homologous 
seeding.  Dr Marakalala included a zinc bound Immobilised Metal Affinity Chromatography 
(IMAC) step in his purification procedure.  This purification step presumably removed non-
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zinc bound MshB, thus producing a more homogeneous sample of zinc bound MshB which 
was easier to crystallise. 
3.3.2 Crystal quality, space group and unit cell determination 
Synchrotron diffraction data were collected from a single crystal at the ESRF beamline 
BM14.  The crystal diffracted to 1.95 Å and was indexed in space group C2.   
The unit cell dimensions were as follows: a = 147.42 Å, b = 71.90 Å, c = 97.69 Å, with 
angles α = 90 °, β = 128.29 °, γ = 90 °.  The data were processed, scaled and integrated using 
XDS (Kabsch, 2010).  Table 3-2 shows the data collection statistics.    
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Table 3-2: Data collection statistics 
Data collection statistics
* 
Data set source BM14a 
Space group C2 
Unit cell parameters    
 
a = 147.72 (Å) 
b = 71.90 (Å) 
c = 97.69 (Å) 
α= 90.0° 
β= 128.29° 
γ= 90.0° 
Molecules in ASU 2 
Resolution range (Å) 76.67-1.95 (2.07 - 1.95) 
No. of observed reflections  221610 (35224) 
No. of unique reflections   58226 (9287) 
Completeness (%) 99.3 (98.8) 
Redundancy 3.8 (3.8) 
Mean (I) /σ(I)  16.66 (3.68) 
Rmerge (%) 8 (49) 
 
 
3.3.3 Molecular replacement and structure refinement 
The diffraction data resulting from the MshB containing crystals was solved by molecular 
replacement as there are models deposited in the Protein Data Bank that were previously 
solved.   
The model used for molecular replacement was chain B of MshB from the PDB entry 1Q7T.  
After an acceptable solution was found by the program Phaser (McCoy et al 2007), the model 
was built into electron density that was unaccounted for using the program Coot (Emsley et 
al 2010).  Refinement was performed using the programs PHENIX (Adams et al 2010) and 
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REFMAC5 (Murshudov et al 2011).  Alternating cycles of interactive model building and 
automatic structure refinement were performed until all major density was accounted for in 
the model and until the R-factor stopped decreasing.  The coordinates were deposited in the 
Protein Data Bank with code 4EWL. 
Refinement statistics are shown in Table 3-3, and the resulting Ramachandran plot is shown 
in Figure 3-12.  It will be shown further on that the strained configuration of Asp-15 might be 
due to its position and likely action as general acid base catalyst in the active site 
Table 3-3: Refinement and model validation statistics 
Refinement statistics 
Resolution range (Å) 76.67 – 1.95 
No. of atoms  
   Protein 
   Ligand/ion 
   Water  
R-factor (%) 
R-free (%) 
Average B value (Å
2
) 
4382 
112 
570 
17 
20 
28.5 
Model validation 
R.m.s. deviations from ideality 
   Bond lengths (Å) 0.019 
   Bond angles (°) 1.413 
Bad rotamers 22 
Ramachandran outliers 9 
R-factor = Σh |Fo - Fc| / Σh Fo where Fo and Fc are observed and calculated structure factor amplitudes of 
reflection h of the working set of reflections, respectively. R-free is equal to R-factor for h belonging to the test 
set of reflections. 
* 
Data in parentheses refer to the highest resolution shell. 
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Figure 3-12: Ramachandran analysis output from MolProbity (Lovell et al. 2003).   
Image made with Kinemage (http://kinemage.biochem.duke.edu).  This analysis shows that six of the amino 
acids have phi and psi angles that are not normally represented.  The amino acids were modelled with these 
angles based on the calculated electron density available, and could not be modelled in any other way.  It is 
important to note that Asp-15 has a strained configuration and that this is likely due to its position and likely 
action as the general acid base catalyst in the active site. 
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3.3.4 Structural analysis of MshB 
Two MshB molecules were found in the asymmetric unit (chain A and B, Figure 3-13).   
 
Figure 3-13: Cartoon representation of solved crystal structure of MshB 
MshB (chain A in green, chain B in gold) showing the PEG (C) molecule at the interface, and the Zn
2+
 ion (grey 
sphere), acetate and glycerol molecules (oxygen atoms in red, carbon atoms coloured the same as the respective 
chain) in both active sites (A and B) present in the unit cell.  The loop which is visualised in this structure for 
the first time is designated by D. 
 
An acetate, zinc ion and glycerol molecule were found in the active site of each of the two 
MshB molecules (Figure 3-14), two molecules of polyethylene glycol 4000 (PEG) were 
found at the interface between the two units (The PEG could be one molecule, but no density 
C 
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was found that connect the two).  A further seven glycerol molecules were found interacting 
with the surface of the protein.  No density corresponding to VU5 was found. 
 
Figure 3-14: Electron density maps of both active sites in the MshB structure solved here. 
The electron density maps show the density (2Fobs-Fcalc) after the atoms were modelled.  The atoms and bonds 
have been modelled as sticks.  The map is contoured at 1 sigma.  MshB chain A (A) is shown in green, chain B 
(B) in gold, zinc atom as a grey sphere. 
 
The density corresponding to chain A enabled every amino acid from1 to 299 to be modeled.  
This is the first time the loop comprising residues 165 to 170 has been interpreted (Figure 
3-15).  The visualization was possibly assisted because the loop is stabilised by interactions 
with Glu-231A and Gln-232A of symmetry related molecules.   
Tyr-142 
His-144 
His-147 
His-13 
acetate 
glycerol 
Tyr-142 
His-144 
His-147 
His-13 
acetate 
glycerol 
Asp-15 
Asp-15 
Asp-95 
Asp-95 
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Figure 3-15: The loop in chain A of MshB which is described here for the first time 
The loop described here for the first time found in Chain A of the structure solved here (green) compared to all 
deposited chains of MshB in the PDB.  Chain B of the structure solved here is shown in orange.  MshB with 
PDB code 1Q7T chain A is shown in light blue.  MshB with PDB code 1Q7T chain B is shown in yellow.  
MshB with PDB code 1Q74 chain A is shown in red.  MshB with PDB code 1Q74 chain B is shown in dark 
blue.  MshB with PDB code 1Q74 chain C is shown in light purple.  MshB with PDB code 1Q74 chain D is 
shown in dark purple. 
 
Chain B is missing density corresponding to the residue range 165 to 172 and was only 
modelled up to residue 298.  The structure revealed a large six-stranded β-sheet sandwiched 
between a series of α-helices (two on one side and three on the other) with a smaller three-
stranded β-sheet creating a “roof” on the active site.   
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In Figure 3-16 the relatively high B factors corresponding to loops labelled A (residue range 
207-217) and B (residue range 163-174) are areas of the protein that are most likely to be 
quite flexible and are located far from the active site.  The high B factors corresponding to the 
loops labelled D (residue range 97-104) are situated very close to the active site and their 
flexibility could indicate an induced fit model which is stabilised when the natural substrate 
(GlcNAc-Ins) binds.   
Figure 3-16: MshB showing the B factor  of the modelled residues in cartoon representation. 
The low B factors in the area of C correspond to the areas surrounding the active site which is likely to be 
stabilised by the bound zinc ion, glycerol and acetate, but also by the interaction between the molecules 
mediated by PEG.  The B factor scale indicates that low B factors are represented by the colour blue, and high B 
factors are represented by the colour red. 
 
There is a cavity that is formed by the two β-sheets and a short bend-forming α-helix next to 
the catalytic zinc ion (Figure 3-17).   
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Figure 3-17: Cartoon representation of Chain A of MshB. 
The zinc ion is shown as a grey sphere and depicts the location of the active site.  (A) is a large β-sheet that is 
sandwiched between the groups of α-helices indicated by (B) and (C).  (D) is the smaller β-sheet that forms part 
of the “roof” of the active site.  The glycerol, acetate and PEG molecules are modeled as sticks, with their 
carbon atoms in green and their oxygen atoms in red. 
 
In both chains the zinc ion was found interacting with N
ε2
 His-147, N
δ1
 His-13 and both 
carboxylate oxygens of Asp-16, which correspond to the previously reported zinc ion binding 
site (Maynes et al. 2003, McCarthy et al. 2003, McCarthy et al. 2004).   
The oxygen atoms of the acetate molecules were found coordinating with the zinc ion in both 
active sites (These occupy similar positions to the water molecules modeled in the Maynes et 
al. (2003) structure).  One acetate oxygen (O) is located in an oxyanion hole formed by the 
Zn
2+
 and the OH of Tyr-142 (Figure 3-18), while the other acetate oxygen (OXT) is found 
within hydrogen bonding distance to the O
δ2
 of Asp-15.  
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The glycerol molecule was found interacting with N
ε2
 His-144, both carboxylate oxygens of 
Asp-95 and N
η1
 Arg-68 in both active sites.  The glycerol molecule in the active site of each 
chain was modeled slightly differently according to the observed density, but were found to 
have similar interactions with the active site residues (Figure 3-14).  Distances between 
relevant atoms are reflected in Table 3-4.  Figure 3-18 gives a graphical representation of the 
information presented in Table 3-4. 
Table 3-4: Distances between relevant atoms in each chain of the structure solved here 
 
Ligand Residue Distance in chain A (Å) Distance in chain B (Å) 
Glycerol 
1-OH N
η1
 Arg-68 2.9 2.7 
1-OH O
δ2
 Asp-95 2.6 2.6 
3-OH O
δ1
 Asp-95 2.8 2.8 
3-OH N
ε2
 His-144 2.8 3.0 
Acetate 
O O Tyr-142 2.6 2.6 
O Zn
2+
 2.0 1.9 
OXT O
δ2
 Asp-15 2.7 2.5 
OXT Zn
2+
 2.6 2.7 
Zn
2+
 
Zn
2+
 N
δ1
 His-13 2.0 2.0 
Zn
2+
 N
ε2
 His-147 2.1 2.0 
Zn
2+
 O
δ2
 Asp-16 2.0 2.1 
Zn
2+
 O
δ1
 Asp-16 2.3 2.3 
Additional distances suggesting hydrogen bonds important for active site geometry 
O
δ1
 Asp-146 O
γ
 Ser-96 2.6 2.6 
O
 δ2 
Asp-146 N Ser-96 2.7 2.8 
O
 δ2 
Asp-146 N
ε2
 His-13 3.0 2.7 
N Asp-146 N
δ1
 His-144 3.1 3.1 
 
Note:  - Atoms are numbered according to the International Union of Pure and Applied Chemistry (IUPAC) and International union of 
Biochemistry and Molecular Biology (IUBMB) joint Commission on Biochemical Nomenclature (CBN) recommended numbering (Moss, 
2009). 
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All the ligands found resolved in the crystal structure are easily explained as the protein had 
been stored frozen in glycerol, and the acetate and PEG are constituents of the crystallisation 
medium. 
 
Figure 3-18: Stereo view of glycerol and acetate in the active site.  
Lines indicate important distances shown in Table 3-4 (dotted lines are potential hydrogen bonds while purple 
lines are interactions with the zinc ion).  The zinc ion is shown as a grey sphere.  Chain A is shown in green and 
Chain B is shown in gold. 
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3.3.5 GlcNAc-Ins modelled into the active site of MshB solved here 
Glycerol is a subcomponent of the glucopyranoside ring of the natural substrate, GlcNAc-Ins, 
and acetate is a product of the reaction arising from the hydrolysis of the amide bond.  It is 
possible to superimpose a model of the natural substrate onto the corresponding atoms of 
glycerol and acetate using Chimera (Figure 3-19).  This exercise clearly positions GlcNAc in 
the active site and enables the identification of specific enzyme substrate interactions. 
 
Figure 3-19: GlcNAc-Ins modeled into the active site of MshB solved here 
(a) The active site atoms from ligands in chain A are shown in green and active site amino acids are shown in 
brown, with nitrogen in blue and oxygen in red.  (b) GlcNAc-Ins (grey) is superimposed almost perfectly onto 
the atoms of the ligands present in the active site. 
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3.4 Modeling of Mca 
Mca is of interest because of the overlapping substrate specificity with MshB.  Mca and 
MshB share almost 33 % sequence identity (and 43 % for the first 200 residues) and are 
predicted to fold in a similar tertiary conformation, as such, a model of Mca could potentially 
be built on the scaffold of MshB to provide insights into the architecture of the active site of 
Mca and therefore shed light on possible active site differences between Mca and MshB.  
This information could prove useful when designing inhibitors of Mca.   
The Mca sequence was submitted to Psipred to retrieve the predicted secondary structure and 
to GenThreader check for the closest predicted structural homologue.  Subsequently this 
information was used in conjunction with the computer program Modeller to model Mca. 
The top scoring multiple alignment from GenThreader, using the Mca amino acid sequence 
as the query, was with a published MshB structure (PDB code 1Q74) (Figure 3-20).  Using 
Modeller, the secondary structure constraints that were predicted using the Psipred server 
(Buchan et al. 2010) (Figure 3-21) were imposed on the Mca amino acid sequence and the 
MshB structure solved here (PDB code 4EWL) was then used as a template to constrain the 
tertiary structure.   
The best zDOPE score achieved was -0.04 (the best zDOPE score achieved when MshB was 
modeled to MshB was -1.12).  Better zDOPE scores are indicated by lower numbers, a 
zDOPE score of less than -1 is an indication of a relatively accurate model (Lasker et al. 
2012).  It would be interesting to attempt to model the first 200 residues of Mca only and 
compare the zDOPE obtained from that study to the zDOPE obtained here (-0.04) to see if 
the divergence of amino acid identity in the last 100 amino acids is causing the zDOPE to get 
worse.  Unfortunately due to time constraints this was not attempted. 
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In order to provide an overview of the Mca model produced by Modeller relative to the MshB 
structure solved here and the secondary structural elements of Mca predicted by Psipred, a 
multiple structural alignment was constructed using Chimera (by superimposing the MshB 
structure solved here onto the Mca model made here).  Figure 3-22 shows this alignment 
together with the structural elements predicted by Psipred.  The mismatches between 
predicted secondary structures and those present in the model arise from the difficulty for 
computer programs to accurately predict protein structures directly from the amino acid 
sequence and add weight to the need for a crystal structure to be solved before any 
meaningful inferences be made regarding the specific 3-dimensional spatial arrangement of 
amino acids in Mca. 
The MshB and Mca models were submitted to CastP (Dundas et al. 2006) and the active site 
pockets were compared.  MshB returned with a solvent-accessible pocket area of 620.9 Å and 
the Mca model with 574.3 Å.  This is unexpected as Mca is able to accommodate much larger 
substrates (MSR) than MshB (GlcNAc-Ins) and therefore it is expected to have a larger 
solvent accessible pocket associated with the active site.  
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- Key ------------------------------------------------------------- 
Conf   = Description of confidence level 
Score  = Raw score from SVM 
p-val  = Probability of false positive 
Epair  = Pairwise energy for model 
Esolv  = Solvation energy for model 
AlnSc  = Sequence alignment score 
Alen   = Length of alignment 
Dlen   = Length of PDB entry 
Tlen   = Length of target sequence 
PDB_ID = PDB identifier (+ chain code + domain code in CATH format) 
------------------------------------------------------------------- 
Confidence levels: 
CERT   p-value < 0.0001 
 
Conf   Score    p-val  Fpair   Fsolv  AlnSc  Alen  Dlen  Tlen  PDB_ID 
CERT   142.831  2e-13  -240.7  -4.1   805.0  277   287   288   1q74A0 
 
>>> Alignment with 1q74A0: 
                  10        20        30        40        50        
         -CCCEEEEEECCCCHHHHHHHHHHHHHHHCCCEEEEEECCCCCCCCCCCCCCCCCCCCCC 
1q74A0   -ETPRLLFVHAHPDDESLSNGATIAHYTSRGAQVHVVTCTLGEEGEVIGDRWAQLTADHA 
             ||  |||||||||    || | |   |  | ||| | || ||      |    |   
Query    MSELRLMAVHAHPDDESSKGAATLARYADEGHRVLVVTLTGGERGEILNP--AMDLPDVH 
         CCCCEEEEECCCCHHHHCCHHHHHHHHHHCCCCEEEEEECCCCCCCCCCC--CCCCCCHH 
                 10        20        30        40        50         
 
 
                  70        80        90          100       110     
         CCHHHHHHHHHHHHHHHCCCCCCEECCCCCCCC---CCCCCCCCCCCCCCCHHHHHHHHH 
1q74A0   DQLGGYRIGELTAALRALGVSAPIYLGGAGRWR---DSGMARSQRRFVDADPRQTVGALV 
               |  | | |   |||     ||         |         |          ||| 
Query    GRIAEIRRDEMTKAAEILGVEH-TWLGFVDSGLPKGDLPPPLPDDCFARVPLEVSTEALV 
         HHHHHHHHHHHHHHHHHHCCCE-EEECCCCCCCCCCCCCCCCCCCCCCCCCHHHHHHHHH 
                   70        80         90       100       110      
 
 
          120       130       140       150            160       170 
         HHHHHHCCCEEEEECCCCCCCCHHHHHHHHHHHHHHHHHHC-----CCCCCCCCCEEEEE 
1q74A0   AIIRELRPHVVVTYDPNGGYGHPDHVHTHTVTTAAVAAAGV-----HPGDPWTVPKFYWT 
            || ||||  ||| |||| ||||   | |  ||  |||        | |||| | |   
Query    RVVREFRPHVMTTYDENGGYPHPDHIRCHQVSVAAYEAAGDFCRFPDAGEPWTVSKLYYV 
         HHHHHHCCCEEEEECCCCCCCCHHHHHHHHHHHHHHHHHCCCCCCCCCCCCCEEEEEEEE 
         120       130       140       150       160       170      
 
 
                180       190        200       210       220        
         ECC-HHHHHHHHHHCCCCCCCCCCCCC-CCCCCCCCCCCCCCCEEEECCHHHHHHHHHHH 
1q74A0   VLG-LSALISGARALVPDDLRPEWVLP-RADEIAFGYSDDGIDAVVEADEQARAAKVAAL 
                             |                        ||           || 
Query    HGFLRERMQMLQDEFARHGQRGPFEQWLAYWDPDHDFLTSRVTTRVECS-KYFSQRDDAL 
         CCCHHHHHHHHHHHHHHCCCCCCHHHHHCCCCCCCCCCCCCEEEEEECC-CHHHHHHHHH 
         180       190       200       210       220        230     
 
 
                 240       250       260       270       280      
         HHCCCCCEECCCCCEEECCCCCEEECCCEEEEEEEECCCCCCCCCCCCCCCCCCCCCC 
1q74A0   AAHATQVVVGPTGRAAALSNNLALPILADEHYVLAGGSAGARDERGWETDLLAGLGFT 
          |||||    |     |            |   ||     |   |  || | ||     
Query    RAHATQI--DPNAEFFAAPLAWQERLWPTEEFELARSRIPA---RPPETELFAGIEP- 
         HHHHCCC--CCCCCCCCCCHHHHHHCCCCCEEEECCCCCCC---CCCCCCCCCCCCC- 
          240         250       260       270          280        
 
 
Percentage Identity = 32.8. 
 
Figure 3-20: Structural alignment reported by GenThreader. 
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The Mca amino acid sequence was submitted to GenThreader.  The alignment with chain A of MshB PDB code 
1Q74 returned with the highest alignment score. 
 
Figure 3-21: Secondary structural elements of Mca predicted by Psipred. 
Secondary structural elements were predicted by entering the Mca amino acid sequence into the Psipred server 
(Buchan et al. 2010). 
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chain A MshB 1   MSETPRLLFVHAHPDDESLSNGATIAHYTSRGAQVHVVTCTLGEEGEVIGDRWAQLTADH 
Mca PRED     1   MSEL.RLMAVHAHPDDESSKGAATLARYADEGHRVLVVTLTGGERGEILNP..AMDLPDV 
Mca ACTL     1   MSEL.RLMAVHAHPDDESSKGAATLARYADEGHRVLVVTLTGGERGEILNP..AMDLPDV 
 
 
chain A MshB 61  ADQLGGYRIGELTAALRALGVSAPIYLGGAGRWRDSGMAGTD...QRSQRRFVDADPRQT 
Mca PRED     58  HGRIAEIRRDEMTKAAEILGVE.HTWLG....FVDSGLPKGDLPPPLPDDCFARVPLEVS 
Mca ACTL     58  HGRIAEIRRDEMTKAAEILGVE.HTWLG....FVDSGLPKGDLPPPLPDDCFARVPLEVS 
 
chain A MshB 118 VGALVAIIRELRPHVVVTYDPNGGYGHPDHVHTHTVTTAAVAAAGVGSGTADHPGDPWTV 
Mca PRED     113 TEALVRVVREFRPHVMTTYDENGGYPHPDHIRCHQVSVAAYEAAGDFCRFPD.AGEPWTV 
Mca ACTL     113 TEALVRVVREFRPHVMTTYDENGGYPHPDHIRCHQVSVAAYEAAGDFCRFPD.AGEPWTV 
 
chain A MshB 178 PKFYWTVLGLSALISGARALVPDDLRPEWVLPRADEIAFGYSDDGIDAVVEADEQARAAK 
Mca PRED     172 SKLYY.VHG...FLRERMQMLQDEFARHGQRGPFEQWLAYWDPDHDFLTSRVTTRVECSK 
Mca ACTL     172 SKLYY.VHG...FLRERMQMLQDEFARHGQRGPFEQWLAYWDPDHDFLTSRVTTRVECSK 
 
chain A MshB 238 V.....AALAAHATQVVVGPTGR..AAALSNNLALPILADEHYVLAGGSAGARDERGWET 
Mca PRED     228 YFSQRDDALRAHATQ..IDPNAEFFAAPLAWQER..LWPTEEFELARSRIPARPP...ET 
Mca ACTL     228 YFSQRDDALRAHATQ..IDPNAEFFAAPLAWQER..LWPTEEFELARSRIPARPP...ET 
 
chain A MshB 291 DLLAGLGF 
Mca PRED     281 ELFAGIEP 
Mca ACTL     281 ELFAGIEP 
 
Figure 3-22: Multiple structural alignment of Mca model and MshB structure solved here. 
“Mca PRED” indicates the Mca amino acid sequence with structural elements predicted by Psipred.  “Mca 
ACTL” indicates the Mca amino acid sequence with actual structural elements found in the model made here.  
Amino acids highlighted in yellow indicate α-helices, while those in green indicate β-strands.  Red residues 
underlined in italics indicate putative important active site residues. 
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The active site of the Mca model presented here (Figure 3-23 and Figure 3-24) shows that 
there is a Lys-19 in Mca where Ser-20 is in MshB.  Where Maynes et al. (2003) predicted 
large differences in the amino acid corresponding to Gln-247 (MshB), it was found that Gln-
242 (Mca) was modelled and presents no amino acid difference.  At the position of Ser-260 
(MshB) though, Ala-255 (Mca) was modeled.   
 
Figure 3-23: Active sites of MshB structure solved here and Mca model made here superimposed. 
MshB is shown in green and Mca in blue.  The major proposed differences in the immediate vicinity of the 
active site are shown; namely Ser-260/Ala-255, Asn-261/Trp-256, Leu-263/Glu-258 and Met-98/Leu-90 (for 
MshB/Mca). 
 
The biggest difference found was in the amino acid that could be in the vicinity of the inositol 
moiety if MSR binds in the active site the same orientation that GlcNAc-Ins is proposed to 
bind, the polar Asn-261 (MshB) is replaced by a bulkier non-polar Trp-256 (Mca).  In the 
current orientation of the tryptophan and with the current position of the loop on which the 
tryptophan is situated, this could cause a steric clash which would be very unfavourable 
energetically (Figure 3-24) and could cause larger differences in other portions of the Mca 
Trp-256 
Asn-261 
Glu-258 
Leu-263 
Met-98 
Tyr-142/137 
His-147/142 
Leu-90 
Ala-255 
Ser-260 
Asp-95/87 
Glu-47/46 
His-13/12 
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protein upon substrate binding.  Other potentially important differences include that Met-98 
(MshB) at the mouth of the active site is replaced by Leu-90 (Mca) and deeper into the cavity 
and away from the active site, the non-polar Leu-263 (MshB) is replaced by an acidic Glu-
258 (Mca). 
 
Figure 3-24: GlcNAc-Ins modeled into the active site of MshB (PDB code 1Q7T), superimposed onto the 
Mca model made here. 
This image shows the natural substrate (GlcNAc-Ins) (pink) that was modelled into MshB with PDB code 
1Q7T, superimposed into the active sites of MshB solved here (white), and the Mca model (blue) that was 
solved here.  The zinc ion is shown in grey.  There is a steric clash between GlcNAc-Ins and Trp-256 in Mca. 
 
To validate the Mca model produced by Modeller, the PDB coordinates were submitted to the 
online web server, ProSA-web (Wiederstein & Sippl, 2007).  The MshB model solved here 
was also submitted for reference.  The Mca model showed better local energy results for the 
first 200 residues as can be seen by Figure 3-25 (a) but the amino acids of the model in the 
last 100 residues have energies that are unfavourable and are likely due to the lower 
percentage of sequence identity in this area of the enzyme compared to MshB, this includes 
Trp-256 
Ser-20 
Lys-19 
GlcNAc-Ins 
Zn2+ 
Asn-261 
Ser-18 
Leu-19 
His-147/142 
His-13/12 
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Trp-256 which is predicted by the model to clash with the proposed binding of the natural 
substrate and this means that in the real structure (due to the uncertainty of the model) might 
in fact be in a different position entirely.  Figure 3-26 (a) shows how the overall z-score of -
5.38 for the Mca structure modelled here is acceptable when compared to z-scores of other 
structures in the Protein Data Bank.  Figure 3-25 (b) and Figure 3-26 (b) show the local 
energy plot and the position of the z-score (-7.35) respectively for MshB (PDB code 4EWL), 
both showing acceptable results. 
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Figure 3-25: Local model quality plots of Mca modeled here and MshB solved here. 
The Mca model (a) showed better local energy results for the first 200 residues, but the amino acids of the 
model in the last 100 residues have energies that are unfavourable and are likely due to the lower percentage of 
sequence identity in this area of the enzyme compared to MshB.  The MshB structure solved here (b) showed 
acceptable energies across the entire sequence. 
 
 
Figure 3-26: Overall model quality plots of Mca modeled here and MshB solved here. 
The overall z-score of -5.38 for the Mca structure modelled here (a) and the overall z-score of -7.35 for the 
MshB structure solved here (b) is acceptable when compared to z-scores of other structures in the Protein Data 
Bank 
  
(a) (b) 
(a) (b) 
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3.5 MshB activity 
The activity of MshB (MshB containing fractions from the S300 Size Exclusion 
Chromatography were pooled and concentrated and it was this sample that was used in the 
activity assays.) with GlcNAc was investigated in order to construct the purification table and 
provide an indication as to the efficacy of the purification protocol.   
3.5.1 MshB assays 
MshB activity was assayed using the method of Huang and Hernick (Huang, Hernick 2011), 
with slight modifications (Chapter 2.5) using protein material purified during this study that 
was concentrated after size exclusion chromatography.   
The assays were performed using substrate concentrations ranging from 5 – 200 mM 
GlcNAc.  The upper limit of GlcNAc solubility is approximately 226 mM in water.  The rate 
of fluorescence was determined using the data that represents a constant rate of increase in 
fluorescence (straight line portion of the curve) which corresponds to the data in the 0 –
 30 min range (Figure 3-27 and Figure 3-28).   
The rate of fluorescence seemed to increase with an increase in substrate concentration which 
is expected.  At 0 mM substrate concentration the rate of fluorescence was found to be 0.01 
fluorescent units per minute (Fl/min) and at 200 mM GlcNAc the rate had increased to 
7.88 Fl/min.  The rates obtained in this study were also compared to those published 
previously by Huang and Hernick (2011), as this would give an indication of how active the 
protein prepared in this study was (Table 3-5).  It is clear that the rates of fluorescence 
obtained in this study were greatly reduced when compared to those rates previously 
published. 
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Figure 3-27: MshB assay showing increase of fluorescence as a function of time. 
This figure shows a comparison of all  the original fluorescent data that was obtained from the range of GlcNAc 
concentrations assayed with MshB.  Each line represents a different concentration of substrate as shown in the 
legend on the right hand side of the table. 
 
 
Figure 3-28: Initial velocity of MshB assays showing increase of fluorescence as a function of time. 
This figure shows a comparison of the initial (first 30 mins) velocity fluorescent data that was obtained from the 
range of GlcNAc concentrations assayed with MshB.  Each line represents a different concentration of substrate 
as shown in the legend on the right hand side of the table. 
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Table 3-5: Equations of each graphical trend line from the initial velocity of the MshB assays and 
comparison of the resulting rates of fluorescence with previously published data. 
 MshB activity 0-200mM 
GlcNAc 
Fluorescence Vs Time 
 
Rate of fluorescence increase 
Fluorescence units per minute 
Huang and Hernick (2011) 
Rate of fluorescence increase 
Fluorescence units per minute 
0mM 
y = 0.01x + 29.12 
R² = 0.33 
 
0.01 0.81 
5mM 
y = 0.16x + 29.99 
R² = 0.95 
 
0.16 73.10 
25mM 
y = 0.60x + 34.92 
R² = 0.92 
 
0.60 226.40 
50mM 
y = 1.14x + 37.01 
R² = 0.98 
 
1.44 298.40 
100mM 
y = 3.56x + 47.97 
R² = 0.99  
 
3.56 407.50 
150mM 
y = 5.21x + 52.15 
R² = 0.99 
 
5.21 448.00 
200mM 
y = 7.87x + 63.49 
R² = 0.99 
 
7.88 No data available 
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3.5.2 Effect of DTT 
Because DTT was substituted for TCEP in the activity assays performed here, a preliminary 
experiment was conducted to investigate whether DTT could be the cause of the decreased 
activity witnessed in the activity assays (Table 3-5).  Figure 3-29 shows that a 10 fold 
increase in DTT corresponded to an almost 10 fold decrease in activity.   
 
Figure 3-29: Plot showing the effect of DTT on MshB activity, showing the rate of increasing fluorescence. 
This plot shows that a ten fold increase in DTT concentration decreases the rate of increasing fluorescence by 
almost ten fold.  The equation derived from each plot is coloured the same as the points of the corresponding 
plot. 
3.5.3 Effect of VU5 
A preliminary investigation was also made into the effect of the putative inhibitor VU5 on 
MshB activity with GlcNAc, as previously inhibition effects had only been performed with 
GlcNAc-Ins (Gammon et al. 2010).   
VU5 was included in assays with and without GlcNAc, and the resulting rates were 
compared. 
The rate of increasing fluorescence observed when 0.1 mM VU5 was incubated with MshB at 
100 mM DTT (note these are extreme inhibitory conditions when MshB is incubated with 
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GlcNAc) (Figure 3-30 A) was found to be approximately twice more than that observed when 
5 mM GlcNAc was incubated with MshB at 10 mM DTT (note these conditions are not as 
inhibitory) (Table 3-5).   
It was found that VU5 was able to increase the rate of fluorescence and potentially recover 
the activity of MshB when the assay was performed in 100 mM DTT (Figure 3.5-10 A and 
B).   VU5 also increased the rate of increase of fluorescence by almost 40 times that of 
GlcNAc when incubated at the same molar quantities (Figure 3-30 C). 
VU5 seems to be a better substrate than GlcNAc, which is not surprising as it has a cleavable 
amide bond together with the glucosyl moiety and phenyl ring (in place of the inositol 
moiety) and therefore the important pharmocophores are represented more in VU5 than in 
GlcNAc.  Despite this, the fact that VU5 seems to be a cleavable substrate needs to be 
investigated further if any significant proposals are to be made.    
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Figure 3-30: Plots showing the effect of VU5 on MshB activity, showing the rate of fluorescence.   
The equation for each trend line is shown on the graph in the same colour of the corresponding plot.  The slope 
indicates the initial velocity of the reaction.  These graphs compare the effect that different concentrations of 
VU5 has on the activity of MshB under inhibiting conditions (high DTT) and under conventional conditions.  
The blue graphs represent conditions without VU5, maroon graphs represent conditions with VU5 and the green 
graph represents conditions with VU5 and without GlcNAc. 
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4 Discussion 
MshB was successfully purified and crystallised, X-ray diffraction data were collected and 
the structure solved by molecular replacement to a resolution of 1.95 Å.  The coordinates 
were also successfully deposited into the Protein Data Bank under the code 4EWL.  Glycerol 
and acetate were found in the active site and GlcNAc-Ins was modelled into the active site 
using glycerol and acetate as a guide.  It will be argued below that the mechanism proposals 
of both Maynes et al (2003) and Huang and Hernick (2012) are inconsistent with the structure 
determined in this study and a new mechanism which resolves these difficulties but remains 
consistent with known kinetic information is proposed. 
The structure of Mca modelled here could indicate some important amino acid differences 
between the active sites of MshB and Mca, however it will be shown that the homology 
modeling done here is not sufficient to explain the differences in substrate specificity.   
The activity of MshB under different assay conditions implied that high concentrations of 
DTT inhibit the enzyme and that VU5 seems to increase the rate of primary amine 
production. 
4.1.1 MshB purification 
The assay conditions used in this study were not optimal (due to the potential inhibitory 
nature of DTT on the reaction) and thus prevent any informative analysis on the kinetic 
properties of the enzyme from being made in this study.  However the resulting purification 
table can still provide an indication of the efficacy of the purification scheme.  The 
purification table for MshB preparation (Table3-1) shows an overall yield of over 70 % and a 
purification of over 70 fold.  The first three steps, namely the cell free extract, ammonium 
sulphate precipitation and the first MshB containing fraction (fraction number 19) from anion 
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exchange chromatography, provided expected trends of yield and purification where the yield 
decreased after each step, the purification factor increased and the total protein content 
decreased.  The last two steps however show some data that initially comes across as 
impossible (for example a 104.31 fold purification and a yield of 120.86 %).  The Q-HP 
sample shows what seems to be an unlikely increase in overall activity which corresponds to 
an irrational yield of over 100 %.  This could possibly be attributed to partial separation of 
inactive and active enzyme.   
When the purification procedure performed in this study is compared to that done by Dr 
Marakalaka (2008) (Table 4-1), it seems that the purification procedure performed in this 
study managed to obtain over 2-fold increase in purification fact r, and almost double the 
percentage yield after Ion Exchange Chromatography.  The increase in apparent activation of 
MshB in later purification steps also seems to be a trend that is observed by Marakalala 
(2008) and Newton et al. (2000). 
The purification procedure in this study was deemed a success because active protein was 
produced and it was sufficiently pure to grow crystals (with the assistance of homologous 
streak seeding with crystals grown using Dr Marakalala’s stored MshB enzyme). 
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Table 4-1: MshB Purification table drawn up by Dr Marakalala (2008)  
It seems that the purification procedure performed in this study managed to obtain over 2-fold increase in 
purification factor, and almost double the percentage yield after Ion Exchange Chromatography when compared 
to that observed by Dr Marakalala.  
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4.2 Biological unit of MshB 
The estimated MW calculated using the SEC standard curve was found to be 45.8 kDa, which 
was larger than the published MW.  The published MW corresponds with the apparent MW 
calculated from SDS-PAGE which is approximately 33 kDa (Newton et al., 2006).   
The molecules in the asymmetric unit reported in this study share an interface, orientation 
and interfacial interactions mediated by PEG, with two of the chains reported in the MshB 
structure with PDB code 1Q74 (Figure 4-1).   
 
Figure 4-1: Chain A (green) and B (gold) of the MshB structure solved here superimposed onto the 
corresponding chains in MshB PDB code 1Q74 (yellow). 
The chains were superimposed using MatchMaker in Chimera.  The zinc ion is shown as a grey sphere and 
PEG, glycerol and acetate are modeled as sticks with their carbon atoms coloured green and gold for chain A 
and B respectively with PEG from 1Q74 in yellow, while oxygen atoms are in red.  This image shows that the 
interface between these two monomers in their respective crystal structures is almost identical. 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
115 
 
Maynes et al. (2003) did not report any information regarding the biological unit of MshB, 
even though their structure (PDB code 1Q74) showed four molecules in the asymmetric unit.  
The PDB coordinates obtained in this study were submitted to the Protein Interfaces, Surfaces 
and Assemblies service (PISA) at the European Bioinformatics Institute 
(http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) and the analysis revealed that the structures 
represented in the PDB coordinates are unlikely to form a complex in solution (Krissinel, 
Henrick 2007).  As the molecules did not show any kind of clear interfacial interactions, one 
can infer that either the crystallisation conditions were not conducive to the biological unit 
forming, or that MshB acts as a monomer.  This is consistent with the findings by McCarthy 
et al. (2004) who stated that “The crystal structure shows no evidence of any oligomeric 
association of the MshB monomers, consistent with size exclusion chromatography, which 
showed a monomeric species.”  Even though prior purification and structural methods had 
shown that MshB is likely to act as a monomer, Newton et al. (2006) found that MshB eluted 
as dimers and tetramers from size exclusion chromatography.  At low Hepes concentration, 
dimers and tetramers were found, and at a higher Hepes concentration, only dimers.  Even 
though the buffer used in the size exclusion chromatography performed by Newton et al. 
(2006) was almost identical to the buffer used in this study, it is believed that in this study 
MshB eluted from the size exclusion column as a monomer.  An in depth study of the buffer 
and salt conditions leading to the various possible mono, di and tetrameric species of MshB 
eluted off size exclusion chromatography could provide clarity on possible inter-molecular 
interactions of MshB monomers.  Even though the formation of higher order structures is 
most likely due to protein aggregation under low ionic conditions, future work could include 
cross-linking experiments under different buffer conditions together with activity assays to 
investigate the biological unit more thoroughly. 
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4.3 X-ray Crystallography 
4.3.1 Co-crystallisation of inhibitor 
VU5 was not visualised in the crystal structure.  One possible reason is that the poor 
solubility of VU5 would hamper its ability to co-crystallise.  There was not enough VU5 to 
allow a full characterisation of the small molecule during this study, therefore details such as 
the exact solubility of VU5 in water are currently unknown.   
Although the mode of inhibition by VU5 is currently unproven, it is likely that competitive 
inhibition is the mode of action of this inhibitor as it is a substrate analogue.  Modeling has 
offered preliminary views of how VU5 might bind into the active site.  If the 
thiophenylglycoside moiety binds in a similar position to the predicted binding site of the 
myo-inosityl-glucopyranoside moiety of the natural substrate, and if their amide bonds 
coordinate with the zinc ion in a similar way, then the tethered plumbagin could be 
accommodated in a cavity within the enzyme.  If this is the case then it would be easy to 
understand why molecules with a longer tether could inhibit the enzyme better (Gammon et 
al. 2010).  The longer tethers allow the plumbagin moiety to be positioned further into a 
pocket near the active site and therefore be stabilised by optimising hydrophobic interactions 
(Figure 4-2).   
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Figure 4-2: Stereo view comparison of VU5 and GlcNAc-Ins modelled into the active site of chain A of the 
MshB structure solved in this study.   
As VU5 is a substrate analogue, it can be modelled into the active site by superimposition over the 
corresponding atoms of the natural substrate.  MshB chain A is shown in green, VU5 in blue, GlcNAc-Ins in 
white and the Zinc ion as a grey sphere.   
 
In the study by Gammon et al. (2010) the pocket which interacts with the plumbagin moiety 
is stated as being made by Val-184 and Leu-185.  In the model presented here however, Val-
184 is too far away to interact and instead the pocket is made by Leu-185, Leu-190 and Leu-
265.  An additional interaction might be made by Lys-237, but that can only be substantiated 
by solving a crystal structure of MshB with VU5 bound because in the current structure it is 
too far (more than 4Å) away to make any meaningful interaction.  Also if VU5 does bind in 
this orientation in the active site, the amide bond is well positioned for catalysis by MshB and 
this could be another reason why VU5 was not visualised in the active site, as the products of 
the reaction could have been displaced by the relatively high concentrations of acetate and 
glycerol.  The fact that MshB seems active against VU5 adds more evidence that supports 
this mode of binding.   
  
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
118 
 
4.3.2 MshB Structure 
The structure of MshB was solved here in space group C2.  There are two other reported 
crystal structures in the Protein Data Bank (PDB), MshB with PDB code 1Q74 has the space 
group P1 (Maynes et al. 2003) in spite of very similar molecular packing to that determined 
here.  MshB with PDB code 1Q7T had the space groupP212121 and had a substantially 
different molecular packing (McCarthy et al. 2003).   
A high percentage of the data (> 98 % complete) were observed with a redundancy of 3.8.  A 
high completeness together with the observed redundancy means that the data collected 
represents almost all the data available and that the single axis rotation data collection 
strategy resulted in each spot being recorded multiple times.  This improved the signal to 
noise ratio,  resulting in better quality data for refinement.  This in turn can be seen by the 
ratio of the merged intensity to the error assigned to the merged intensity of 16.66.  The 
Rmerge obtained in this study (8 %) is good too as it is an indication of the agreement between 
multiple measurements of the same reflections, lower values indicating a better agreement.  
The mosaicity observed is 0.21 ° which is an acceptable value (mosaicity angles below 1 ° 
are considered acceptable).  Mosaicity is an indication of the degree of orientational 
divergence of the mosaic blocks that make up the crystal.  It could be improved by exploring 
the cryo conditions under which the crystal was frozen.  Often the mosaicity can be increased 
when the freezing conditions are not optimal (Jeffrey 2006). 
Approximately 5 % of the data were retained for model validation using the Rfree statistic.  
The correlation between the resolution and Rfree was found to be below average for structures 
deposited before the year 2000.  This is an indication that the model is fairly accurate 
(Kleywegt, Jones 2002).  The difference between R-free and R-factor is 0.03; if the 
difference is less than 0.05 then the possibility of model bias is low enough to be acceptable 
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(Kleywegt, Jones 2002).  The Ramachandran plot (Ramachandran et al. 1963) from 
MolProbity (Lovell et al. 2003) showed over 96 % of all residues falling in the favoured and 
allowed regions, an indication of correctness in the backbone geometry of all structures 
(Figure 3-12).  This analysis showed that six of the amino acids have phi and psi angles that 
are not normally represented.  The amino acids were modelled with these angles based on the 
calculated electron density available, and could not be modelled in any other way.  In 
particular the strained conformation of Asp-15 could be explained by its involvement in the 
active site.  Interaction with acetate bound in the active site, in addition to the active site 
environment, could cause a strained conformation.  The model had reasonable bond lengths 
and bond angles, as judged from the root mean square deviation (r.m.s.d.) values that are 
within the acceptable range for structures of similar resolution. 
The structure solved here, together with those previously solved, allow us to observe a 
conformational change in the flexible loop located near the active site of MshB (Figure 4-3).  
The changes are indicative of an induced fit model where the active site geometry is fairly 
unstable or flexible prior to substrate binding, but assumes a stable conformation after the 
substrate binds to the active site, this causes significant changes in the areas surrounding the 
active site which allow the substrate to be positioned for catalysis.  Specifically the binding of 
Asp-95 to the substrate could trigger Asp-146 binding to Ser-96 and a closing of the loop 
with Met-98 aligning with the inositol moiety of the natural substrate.    
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Figure 4-3: Conformational changes in MshB upon binding of substrate.  
(a) A ribbon diagram of chain A of MshB from Maynes et al., (2003) (grey) is superimposed on the glycerol 
bound form solved here (brown and green). The modelled substrate is shown with pink carbon atoms. The 
comparison highlights the functionally important conformational change in the residues that form the substrate 
binding pocket. The rigidity of the loop shown in green (residues 95 to 107) is increased as a result of the 
interaction of the substrate with Asp-95. These changes bring about the binding pocket for the D-myo-inositol 
ring. In particular, according to our model, Met-98 moves so as to interact with the proposed position of the 
inositol ring of the natural substrate GlcNAc-Ins. (b) In the form of MshB in which no ligands are bound in the 
active site pocket, Asp-95 forms two hydrogen bonds, one to each of the carboxylate oxygens, from the main 
chain NH groups of Glu-44 and Glu-45. In the glycerol bound structure, two new hydrogen bonds to the 1-OH 
and 3-OH of the glycerol respectively, are formed. This causes a number of changes that result in the movement 
of parts of the molecule which are coloured green. Residues 100-103 are invisible in the MshB structure in 
which no ligands are bound in the pocket, indicating the high flexibility of the region.  (Figure and caption 
adapted from Broadley et al. (2012)). 
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The movement of Tyr-142, when the structure reported here is compared to all known chains 
of MshB in the PDB, shows another important structural change in the active site, and 
provides structural evidence for the proposal by Huang and Hernick (2012) that Tyr-142 
plays an important role in stabilizing the tetrahedral intermediate and could play an important 
part in product removal.  Tyr-142 has rotated about its Cα-Cβ bond such that in our structure 
it is found interacting with the acetate, and in the other structures it is found pointing out and 
away from the active site (Figure 4-4).   
 
Figure 4-4: Stereo view showing the movement observed for Tyr-142 in all known crystal structures of 
MshB, and the formation of the oxyanion hole.   
The rotation about the Cα-Cβ bond of Tyr-142 is visible as the position it occupies is different in every instance 
of MshB structure solved thus far. It is important to note that in the presence of acetate the observed position is 
almost identical in both chains demonstrating the role this residue plays in the oxyanion hole.  This position also 
resembles the hypothetical position suggested by Huang and Hernick (2012).  Chain A of the structure solved 
here is shown in green, Chain B in gold.  The other structures currently deposited in the PDB are shown in thin 
wires, yellow representing  Tyr 142 from chain B in the structure with PDB code 1Q7T, red representing A from 
1Q74, light purple representing C from 1Q74, dark blue representing B from 1Q74, dark purple representing D 
from 1Q74 and light blue representing A from 1Q7T. 
 
McCarthy et al. (2004) modeled GlcNAc into the active site of MshB based on the β-octyl 
glucoside (BOG) molecule that was found in the A chain of their crystal structure.  The atoms 
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of the BOG that were found binding to Asp-95 (MshB with PDB code 1Q7T, chain A) 
correspond very closely to the atoms of the bound glycerol in this structure, and the BOG 
found in chain B binds in a similar position to acetate (Figure 4-5).   
 
Figure 4-5: Stereo view of ligands found in the active sites of MshB structures with PDB codes 1Q7T and 
4EWL, superimposed upon one another.  
The β-octyl glucosides crystallised in the MshB structure with PDB code 1Q7T (chain A in cream and chain B 
in light blue), were superimposed onto the glycerol and acetate molecules found in the active site of the solved 
structure (chain A in green and chain B in gold).  
 
The glycerol molecule was found to bind to each chain in a slightly different orientation, but 
they were both found to be interacting with Asp-95 and His-144.  The two distal oxygen’s of 
the glycerol molecule seem to bind in a similar position to the β-octyl-glucoside (BOG) from 
the crystal solution of MshB by McCarthy et al. (2004).  This indicates the importance of the 
amino acids that they interact with, namely Asp-95 and His-144, in substrate recognition. 
 
There was an acetate molecule that was found bound to the zinc ion in each active site.  The 
acetate together with the glycerol could indicate a possible lead towards new drug 
development.  The acetate molecule also resembled the geminal diol that was formed when 
the ester containing kAW inhibitor was co-crystallised with another zinc ion dependent 
peptidase, angiotensin converting enzyme (ACE) (PDB code 3BKL) (Watermeyer et al. 
BOG 
BOG 
acetate 
glycerol 
zinc 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
123 
 
2008) that has been extensively studied at the University of Cape Town.  Despite the finding 
by Gammon et al. (2010), that a non cleavable substrate analogue was not a very successful 
inhibitor of either Mca or MshB, this avenue has perhaps not been exhaustively investigated 
and my still prove fruitful.  Gammon et al. (2010) only produced a compound (with an ester 
in place of the amide) with a cyclohexyl moiety in place of the inositol moiety.  This part of 
the substrate has been shown to be very important in substrate recognition by MshB and by 
simply replacing the inositol moiety with a cyclohexyl moiety (keeping everything else in the 
natural substrate the same) the activity is reduced by more than 17 times (Gammon et al. 
2010).  For example, if a substrate analogue inhibitor with an ester was thoroughly 
investigated rather than an amide, one might get inhibition in the same manner that kAW 
inhibits ACE. 
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4.3.3 Catalytic mechanism 
Previously researchers have hypothesized that during catalysis, the tetrahedral transition state 
of the amide carbonyl would be stabilised by the zinc ion and the side chain of His-144 
(Newton, Buchmeier & Fahey 2008, Jothivasan, Hamilton 2008, Maynes et al. 2003, Fan et 
al. 2009).  It is felt that the orientation of histidine 13 and 144 in the active site of MshB 
Chain A deposited under PDB code 1Q7T were modelled incorrectly.  This discrepancy may 
have given rise to confusion in later work (for example in the study by Huang and Hernick, 
2012).   
In the MshB structure that was solved here, His-144 was shown to be interacting with the 
bound glycerol molecule and Tyr-142 was found interacting with the acetate coordinated to 
the zinc ion.  It is proposed that, as opposed to previous authors (Maynes et al. 2003, 
Jothivasan and Hamilton 2008, Newton, Buchmeier & Fahey 2008 and Fan et al. 2009) who 
believe that His-144 acts as the general acid catalyst, His-144 instead acts to stabilise 
substrate binding, while the transition state and resulting acetate is stabilised by the oxyanion 
hole formed by the zinc ion and Tyr-142, and that Asp-15 acts as both the general base and 
general acid catalyst (Figure 4-6).   
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Figure 4-6: Schematic of the catalytic mechanism for MshB that is proposed here. 
Proposed catalytic mechanism of MshB showing how Tyr-142 is implicated in stabilising the tetrahedral 
intermediate state instead of His-144 and that Asp-15 acts first as the general base catalyst and then as a general 
acid catalyst. 
 
Figure 4-7 shows the catalytic mechanism using deposited structures and models of ligands.  
McCarthy et al. (2004) support the hypothesis that His-144 binds to the substrate and is not 
involved in stabilizing the tetrahedral transition state (McCarthy et al. 2004).  The 
biochemical study published by Huang and Hernick (2012) explored the effect of different 
active site mutations on the activity of the enzyme (Figure 4-8).  It was shown that Tyr-142 is 
involved in the catalytic mechanism and believed to occupy multiple conformations during 
the catalytic cycle.  The structure reported here provides structural confirmation that Tyr-142 
indeed plays an important role in the catalysis of the substrate.  Huang and Hernick (2012) 
show that mutation of Asp-146 to alanine also decreases activity, and increases KM by a 
factor of more than 10.  They state that this is due to the interaction of Asp-146 with His-13 
and/or His-144.  Our structure indicates that an interaction with His-13 is possible but that an 
interaction with His-144 is unlikely as the closest approach of an Asp-146 oxygen to His-144 
is 3.3 Å and this is to a carbon atom.  Instead we propose that Asp-146 instead interacts with 
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Ser-96 and His-13 to stabilise the region surrounding the active site when the substrate binds.  
The biochemical data (Huang and Hernick, 2012) supports our model in that the pKa values 
of the functional groups in enzymes in which either His-144 or Asp-146 were mutated were 
the same as those of the wild-type protein.  This suggests that neither of these residues are 
involved in ionizations that affect the catalytic events.  However when Tyr-142 and Asp-15 
were mutated to alanine, the upper and lower pKa values were lost which indicate that these 
residues play an integral role in the catalytic mechanism and are responsible for the observed 
pKa values. 
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Figure 4-7: Models supporting the catalytic mechanism proposed here.  
See caption on next page.  
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Figure 4-7 caption: 
(a) The active site prior to substrate binding (Maynes et al. (2003); PDB entry 1Q74, chain A). Two water 
molecules coordinate to the Zn
2+
 ion. Both Tyr-142 and Asp-95 point away from the active site. (b) Part of the 
GlcNAc-Ins as modelled into the active site. The D-myo-inositol has been omitted from the drawing as it 
obscures Tyr142. The GlcNAc-Ins location is informed by the observed positions of glycerol and acetate in the 
structure reported here. Conformational changes involving Tyr-142 and Asp-95 have occurred. One water has 
been displaced, while the other water is poised to perform a si-face nucleophilic attack on the amide carbonyl C 
atom assisted by Asp-15. (c) The modelled tetrahedral intermediate stabilized by the oxyanion hole formed by 
Zn
2+
 and by Tyr-142. The carboxylate of Asp-15 is protonated. In order achieve the stereoelectronic alignment 
for the amino group to acquire the proton it is necessary for the carboxylate to move slightly. We speculate that 
this movement may be induced by interaction between Asp-15 O
δ2
 and 3-OH of GlcNAc. (d) The product 
acetate with one O atom hydrogen-bonded to Asp-15 and the other located in the oxyanion hole based on the 
structure described here.  
 
 
 
Figure 4-8: pH rate profiles figure take from Huang and Hernick (2012). 
The pH dependence of the MshB-catalysed reaction is shown for WT (O), Asp-15 to Ala (   ), Tyr-142 to 
Ala (   ), Tyr-142 to Phe (   ), His-144 to Ala (    ), and Asp-146 to Ala (    ) as described in Huang and Hernick 
(2012).  
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Huang and Hernick (2012) dismiss the idea of a single amino acid performing as a general 
acid – base catalyst due to results obtained in two experiments.   
Firstly because the decreases in activity for the Asp-15 (530 fold) and His-144 (180 fold) 
mutations to alanine were less than that expected for a single amino acid functioning as a 
bifunctional general acid – base catalyst.  Huang and Hernick (2012) state that for a 
bifunctional general acid – base catalyst, one would expect a decrease in activity of 103 – 105 
fold when that amino acid is mutated.  However, the references that they cite to support this 
expectation involve mutations of glutamic acid and histidine, and not an aspartic acid 
(Jackman, Raetz and Fierke 1999, Cha and Auld 1997, Wetterholm et al 1992), therefore 
their expectations might not necessarily be appropriate in this circumstance.   
Jackman et al 1999 investigate an enzyme (UDP-3-O-(R-3-hydroxymyristoyl)-N-
acetylglucosamine deacetylase or LpxC) that in a previous paper had been isolated with a 
mutation from His-19 to a tyrosine (Hyland, Eveland and Anderson 1997).   Hyland, Eveland 
and Anderson (1997) speculated that this mutation disrupted a metal ligand, and that this was 
the reason for the decrease in activity.   
Cha and Auld (1997) describe a mutation in an enzyme (matrilysin) where Glu-198 was 
mutated to aspartic acid, cysteine, glutamine and alanine.  They found a 4.1, 160, 590 and 
1900 fold decrease in activity respectively.  According to the structure solved by Browner, 
Smith and Castelhano (1995), Glu-198 is not located in the active site and it serves to help 
coordinate one of two structural calcium ions visible in the enzyme crystal structure.  
Disruption of this amino acid must lead to structural effects in the active site and cause a loss 
of activity. 
Wetterholm et al (1992) investigated mutations of Glu-296 from human leukotriene A4 
hydrolase.  A mutation from glutamic acid to glutamine actually increased the enzyme’s 
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epoxide hydrolase activity by 1.5 fold but decreased the enzyme’s peptidase activity by 466 
fold.  A mutation to alanine decreased the epoxide hydrolase activity by 8 fold and decreased 
the peptidase activity by 700 fold.  The active site glutamic acid in this family of 
metalloproteases is proposed to act as the general base catalyst in the hydrolysis of peptides 
(Helgstrand et al 2011). 
The second experiment that Huang and Hernick (2012) used to infer whether the catalytic 
mechanism used a single amino acid as the general acid – base catalyst or two amino acids, 
one being the general acid and the other as the general base catalyst, was to see if they 
observed any solvent isotope effects when activity of MshB mutants was measured in 95 % 
D2O and compared to measurements taken in H2O.  Solvent isot pe effects of 0.8 and 5.4 
were observed when Asp-15 and His-144 were mutated respectively.  Huang and Hernick 
(2012) believe that the observed effects are consistent with a mechanism that uses a general 
acid – base pair.  It has been shown here that His-144 is involved in substrate binding and is 
very important in positioning the substrate, so there are many subtle changes that could be 
taking place with regards to the way that the substrate binds when His-144 is removed.  To 
propose a mechanism based on the solvent isotope effect that is observed could be premature, 
as there are other possible reasons for observing a solvent isotope effect.  For example, the 
substrate could be interacting with the active site slightly differently and the D2O could be 
causing multiple isotope effects that we are not aware of, including secondary effects.   
Huang and Hernick (2012) were not in a position to consider key information that is detailed 
here for the first time, in particular, the proximity of N
ε2
 His-144 to 3-OH of the bound 
glycerol is clearly indicative of hydrogen bonding.  This being the case, the atom directed 
towards the scissile bond is a carbon which is located ~5.5A away making it impossible for 
His-144 to act as an acid catalyst.  In addition previous structures have misinterpreted the role 
of Asp-146 which is uniquely well defined in the structure described here.  This is not 
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hydrogen bonded to His-144 as depicted by Maynes et al. (2003) but to Ser-96, stabilising the 
highly mobile loop that brings Met-98 to align with the proposed binding position of the 
inositol moiety of the natural substrate, and to His-13, stabilising the coordination of His-13 
to the zinc ion.  There is potentially a hydrogen bond from the backbone N of Asp-146 to 
N
δ1 
His-144 (depending on the protonation state of the Histidine) which would aid in the 
stabilisation of His-144 and thus the ability to aid alignment of the natural substrate when 
bound in the active site. 
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4.4 Modeling of Mca 
Secondary structure constraints that were predicted using the Mca amino acid sequence 
submitted to Psipred (McGuffin, Bryson & Jones 2000) were entered into the Modeller script 
and the MshB structure solved here was then used as a template to constrain the tertiary 
structure.  The best zDOPE score achieved was -0.04 (the best zDOPE score achieved when 
MshB was modeled to MshB was -1.12).   
Maynes et al. (2003) modelled Mca and reported that the only major difference between the 
two models (Mca vs MshB) is that there is a Lys-19 in Mca where there is a Ser-20 in MshB.  
They suggest that this is where the glucosyl moiety could bind and this difference could 
cause a steric clash in Mca with the glucosyl moiety on the MSH.  The substrate of Mca 
(MSH conjugated to a toxin, MSR) also contains the glucosyl moiety and therefore either 
binds in a different orientation or there are differences that might compensate for the 
unfavourable binding, by residues that bind to the AcCys residue of MSH, Gln-247 and Ser-
260, but they were unable to model this region of Mca. 
The Mca model generated in this study also shows that Lys-19 in Mca is located where Ser-
20 is in MshB, but taking the glycerol binding information together with the BOG binding 
information (McCarthy et al. 2004) it strongly suggests that the glucosyl moeity actually 
binds to Asp-95.  With regards to the question of substrate specificity, in the MshB structure 
there is the possibility of a steric clash between Asp-16 and the Acetyl group on MSH and 
could explain why MSH is a poor substrate for MshB, in the Mca model there is slightly 
more space in this region as the Asp-16 is replaced by Ser-18.   
Where Maynes et al. (2003) predicted large differences in the position of Gln-247 (MshB) it 
was found in our model that Gln-242 (Mca) occupied the same position and thus no 
difference was observed.  At the position of Ser-260 (MshB), Ala-255 (Mca) was found.  The 
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biggest differences that were found, were in the amino acids that are believed to bind to the 
inositol moiety of MSH/MSR.  The polar Asn-261 (MshB) is replaced by a bulkier non-polar 
Trp-256 (Mca).  Another big difference at the mouth of the active site is that the Met-98 
(MshB) is replaced by Leu-90 (Mca).  As one moves deeper into the cavity and away from 
the active site, the non-polar Leu-263 (MshB) is replaced by acidic Glu-258 (Mca).  This 
change could influence the recognition of R-groups that are conjugated to MSH. 
The predicted structural elements do not match up perfectly with the elements present in the 
model, this is an indication as to the unreliable nature of predictions made using a query with 
a single sequence, however the differences are discussed below and still provide a platform 
from which to work from with regards to designing mutagenesis experiments.   
A β-strand predicted (but not present in our model) from residue 80 to 83 is close (almost 10 
amino acids away) to the active site and would form part of the large β-sheet that runs 
through the center of the protein.  Forming part of the β-sheet could influence the geometry 
of the active site slightly.  Another potentially important prediction that is not accounted for 
in the model is a helix predicted from residue 254 to 259.  This predicted helix holds Trp-256 
and forms part of the “roof” of the active site which is implicated in recognition of the 
inositol moiety of the natural substrate MSR.  These alterations might have a consequence 
that would account for the differences in substrate specificity.  Further work could include 
mutating these residues in Mca such that a β-sheet is not predicted from residue 80 to 83 and 
that the Trp-256 is changed to Asn.  These mutations could alter the activity and substrate 
specificity of Mca and could provide more insight into the substrate specificity of these two 
enzymes. 
Pockets observed in the Mca model solved here were analyzed using CastP (Dundas et al. 
2006), viewed in Chimera (Pettersen et al. 2004) and compared to those of the MshB 
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structure solved here.  The active site cavity in the modeled Mca structure was smaller than in 
the MshB structure.  This does not account for Mca’s ability to hold larger structures in its 
active site, if the substrate binds into the active site in a similar fashion to MshB, as proposed.   
The substrates of Mca (MSH conjugated to an electrophile) are inherently bigger than the 
MshB substrate GlcNAc-Ins.  This information together with the replacement of Asn-261 
(MshB) with the bulkier Trp-256 (Mca) suggest that there must be greater folding differences 
between MshB and Mca that account for the differences in substrate specificity between these 
two homologous enzymes, and that these differences cannot be fully investigated by 
modeling alone.   
The active site seems to be able to be quite variable as it is surrounded by large loops that 
could accommodate various sizes of substrate (MSR).  It would be difficult to interpret the 
amount of movement that these loops can accommodate, without having transition state 
analogues bound in the crystal structures. 
Further work is needed to conclusively investigate the substrate specificity of these two 
enzymes.  It would be very interesting to perform mutagenesis experiments in an attempt to 
convert each enzyme’s activity to act on the other enzyme’s substrates. 
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4.5 MshB Activity 
4.5.1 MshB assays 
MshB activity was assayed with VU5 and GlcNAc (N-acetyl Glucosamine) using an assay 
adapted from Huang and Hernick (2011).  GlcNAc is used as it is far cheaper and easier to 
obtain than the natural substrate, GlcNAc-Ins, and it has been used before in published 
articles to measure the enzyme kinetics of MshB (Huang and Hernick 2011) and measure the 
pH dependence of MshB and mutants thereof (Huang and Hernick 2012). 
It must be noted that there are differences between the assay published by Hernick and Huang 
(2011) and that published by Gammon et al. (2010).  Gammon et al. (2010) used half the 
concentration of Hepes and NaCl, and did not include any reducing agent, whereas Huang 
and Hernick (2011) used 50 mM Hepes and 50 mM NaCl, and included 1 mM TCEP to 
maintain a reducing environment.   
The differences between the Huang and Hernick (2011) published method and the method 
that was used in this study will be discussed below.  The samples in this study were not 
centrifuged after precipitating the enzyme with TCA.  This was done to increase the speed at 
which the assay can be completed and to decrease the cost involved in assaying hundreds of 
reactions.  As long as the concentration of enzyme was kept constant, this would not affect 
the measurement of the rate of the reaction.  It would only affect the baseline value as the 
protein would obviously have primary amines that would react with the fluorescamine 
reagent.  The reaction volume in this study was also increased from 200 µl to 1.5 ml.  This 
was done to reduce the chance of pipetting error when pipetting very small volumes.   
The assay as implemented in this study has DTT substituted for TCEP.  DTT was freely 
available in the lab and is cheaper to purchase than TCEP.  As TCEP is a much stronger 
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reducing agent than DTT (Han, Han 1994), together with guidance from colleagues in the 
lab, 10 mM DTT was added to compensate.  This change in the assay was not useful for 
detailed kinetic analysis because, in hindsight, DTT is likely to be an inhibitor.  It did 
however enable the relative activity of the MshB preparations to be assessed.  The assay was 
used in a preliminary manner to ascertain whether or not active protein was being produced 
and to give an indication as to the effect of VU5 on the activity of MshB for future studies. 
The differences between the derivitisation method published by Huang and Hernick (2011) 
and the method used by Gammon et al. (2010) (adapted from Anderberg, Newton & Fahey 
1998) will be discussed below. 
The Anderberg, Newton and Fahey (1998) method utilises derivitisation of primary amines 
by 6-aminoquinolyl-N-hydroxysuccinamidal carbamate (AccQ-Fluor) whereas the Huang and 
Hernick (2011) method utilises derivitisation of primary amines by fluorescamine (FSA).   
With AccQ-Fluor derivitisation, the AccQ-Fluor must be incubated with the protein sample 
for 1 min at room temperature, followed by 10 min at 55 °C, after which the sample has to be 
eluted off a reverse phase column using High Pressure Liquid Chromatography (HPLC) 
which takes approximately 30 min (not taking into account the time needed to prepare the 
column for use and the time needed to prepare the column for storage again).  Additionally 
only one sample can be eluted at a time.  With FSA derivitisation however, the FSA must be 
incubated for approximately 10 min in a 96 well plate before the fluorescence can be 
determined by a plate reader with fluorescent capabilities.  The time needed to assay 96 
samples is approximately 48 hours when using AccQ-Fluor, and only 10 min when using 
FSA.  The benefits for using a system involving FSA and 96 well plates are increased further 
when taking into account the amount of reagent used in each method. 
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4.5.2 Effect of Glycerol on MshB activity 
Huang and Hernick (2012) demonstrate a loss of activity in the presence of high 
concentrations of glycerol and sucrose which they attribute to an increase in the viscosity of 
the solution. The structure solved here shows glycerol located in the active sites of both 
chains A and B.  These interactions are similar to the hydrogen bonding interactions with the 
glucopyranoside ring of BOG (McCarthy et al., 2004) and suggest that similar interactions 
position the natural substrate in the active site of MshB.  Structural evidence therefore 
suggests that the observed loss in activity could be attributed to competitive inhibition in 
addition to possible viscosity effects (Brouwer & Kirsch, 1982).  This could also be another 
reason why VU5 was not seen in the crystal structure as the enzyme had been stored with 
20 % glycerol which is approximately 2.2 M glycerol.  This high concentration of glycerol 
would have been diluted down to approximately 0.23 M when the protein was diluted to the 
appropriate concentration for crystallisation, but could have still out-competed the even lower 
(approximately 500 µM) concentration of VU5 present in the crystallisation conditions. 
  
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
138 
 
4.5.3 Effect of DTT and VU5 on MshB activity 
The rates of fluorescence obtained during activity assay measurements made in this study 
were compared to those obtained in the study by Hernick and Huang (2011) in order to 
crudely investigate the activity of the MshB produced in this study.  Initially it seemed that 
the MshB that was produced in this study was less active than previously published by Huang 
and Hernick (2011).  However, after noticing that an increase in DTT concentration further 
inhibits the activity of MshB with GlcNAc, we propose that the difference in activity was due 
in fact to DTT acting as an inhibitor.  Perhaps by performing activity assays over a range of 
DTT concentrations alongside experiments with a similar range of TCEP concentrations, the 
apparent inhibition by DTT could be further investigated.  Unfortunately due to time and cost 
constraints the necessary experiments could not be performed with respect to investigating 
the effects of DTT on MshB activity. 
Under conditions containing 100 mM DTT, the amount of GlcN produced by the hydrolysis 
of 200 mM GlcNAc by MshB was reduced by almost 89 % compared to data obtained with 
10 mM DTT.  If 1 mM VU5 was added to the above reaction, then it seems that the activity 
was restored.  If 0.1 mM VU5 was added, then the activity was only partially restored.  The 
mechanism of action by VU5 that prevents DTT from inhibiting MshB activity is unknown 
and requires further investigation. 
It must be noted that there is no noticeable auto-fluorescence that takes place by GlcNAc, 
VU5 or even when they are incubated together without MshB.   
Under conditions containing 100 mM DTT, when 200mM GlcNAc and 0.1mM VU5 is 
incubated with MshB, the rate of fluorescence is more than 4 times that of 200mM GlcNAc 
and MshB and more than 11 times than that of 0.1 mM VU5 and MshB.  It is suggested that 
the combination of VU5 and GlcNAc somehow activates the production of primary amines 
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by MshB.  Whether the amines produced come from VU5 or GlcNAc, or a mixture of both 
sources, remains unknown. 
Thus while attempting to assay the published inhibitory action of VU5 using GlcNAc as the 
substrate, it was noticed that VU5 could be a better substrate than GlcNAc.   
When equivalent amounts of GlcNAc and VU5 were incubated with MshB separately, the 
rate of increasing fluorescence in the VU5 containing reaction was almost 23 times faster 
than the rate of the GlcNAc containing experiment.  Simultaneous incubation of VU5 and 
GlcNAc led to a rate of fluorescence almost 1.12 times that of VU5 alone. 
The increased activity of VU5 compared to GlcNAc can possibly be attributed to the VU5 
having a phenol ring in place of the inositol when compared to the natural substrate, GlcNAc-
Ins, whereas GlcNAc does not have the corresponding ring.  The inositol group has been 
shown to increase substrate specificity (Newton et al. 2006, Gammon et al. 2010) and 
because the VU5 has a cleavable amide bond, it is not particularly surprising that it could 
have increased activity when compared to GlcNAc. 
There is also the possibility that the interaction of GlcN and VU5 or the interaction of VU5 
and fluorescamine, causes an increase in fluorescence that is un-related to the amount of free 
primary amine reacting with the fluorescamine, however this also needs to be investigated 
further.   
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5 Concluding remarks 
In this study it was shown that glycerol and acetate interact with the MshB active site and 
bind well enough to be visualised by X-ray crystallography.  This supports previous 
proposals with regards to the orientation of binding of the natural substrate, and reiterates the 
importance of specific residues in substrate/inhibitor recognition.  Studies have so far shown 
that mshB and mca mutants are more resistant to isoniazid and ethionamide, however perhaps 
if these enzymes are chemically inhibited, and are not made inactive by mutation or deletion, 
the isoniazid and ethionamide sensitivity could be retained while MSH levels are kept as low 
as possible, thus causing the bacteria to become more vulnerable to reactive oxygen species 
and other toxins and antibiotics.   
An alternate catalytic mechanism is proposed where instead of His-144, Tyr-142 stabilises 
the tetrahedral intermediate while His-144 helps to stabilise substrate binding in the active 
site.  Thus it is believed that His-144  neither forms part of the oxyanion hole as suggested by 
Maynes et al. (2003) nor does it act as a general acid catalyst as suggested by Huang and 
Hernick (2012).  Rather it is important in substrate recognition (assisting in the changes 
necessary for the suggested induced fit of the substrate into the active site) and in binding the 
GlcNAc moiety of the natural substrate via a hydrogen bond between N
ε2 
His-144 and the 6-
OH of the GlcNAc moiety. 
Future work needs to include a full characteristic and kinetic study of the effect of VU5 and 
DTT on MshB activity with GlcNAc and GlcNAc-Ins, this will clarify the specific conditions 
under which MshB is inhibited or activated.  
Non hydrolysable substrate analogues that co-crystallise with the MshB would be a great step 
forward in fully elucidating the active site geometry.  This would also potentially be of use in 
Mca co-crystallisation attempts and could create the opportunity to make inhibitors that result 
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in a geminal diol for example, like the kAW inhibitor of the angiotensin converting enzyme 
(ACE) (Watermeyer et al. 2008).  ACE is also a zinc ion dependent peptidase and the 
geminal diol that forms in the active site when co-crystallised with kAW resembles the 
proposed transition state between substrate and product, however the inhibitor is non-
hydrolysable and therefore binds very tightly to the target active site.  This could be a goal for 
the inhibition of MshB and Mca.  If a substrate analogue inhibitor could be produced (that 
included pharmocaphores important in substrate recognition) that is non-hydrolysable (for 
example containing and ester instead of an amide) and could form a geminal diol, then 
perhaps it could experience a similar success to the kAW inhibition of ACE. 
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7 Appendix A: Densitometry analysis 
Protein purity was estimated by densitometry using the computer program ImageLab (Bio-
Rad) (Appendix A).  SDS-PAGE analysis was carried out on samples from S300 size 
exclusion chromatography experiments and subsequently analysed with ImageLab.  Lanes 
were created manually, while the bands were first detected automatically using the high 
sensitivity setting and then manually adjusted as necessary.  The average purity was 
calculated by averaging the individual percentage purity of the hypothetical MshB containing 
bands from lane 2 to 5.  The calculation is shown below: 
74.6/100 + 84.5/100 + 85.5/100 + 93.4/100 = 338/400 
(338/400) / 4 = 84.5% average purity. 
Figure 7-1 on the following page shows the image th t was analysed.  Lane 1 is the protein 
molecular weight marker, lane 2 represents sample that eluted at 166 min, lane 3 represents 
sample that eluted at 173 min, lane 4 represents sample that elute at 176.5 min and lane 5 
represents sample that eluted at 183.5 min.  These samples cover the apex of the peak from 
the chromatogram in Figure 3-10 (a).    
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Figure 7-1: Densitometric analysis of SDS-PAGE from samples taken from S300 chromatogrphy  
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